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DEVELOPMENT OF NEXT-GENERATION VIRUS-LIKE PARTICLES
TARGETING HPV

BY

MITCHELL RYAN TYLER

B.A., Biochemistry, University of New Mexico, 2006

Doctor of Philosophy
Biomedical Sciences

ABSTRACT

Virus-like particles (VLPs) comprised of viral structural proteins that selfassemble into particles resembling the native virion represent a relatively novel
vaccine development strategy. Both safe and immunogenic, VLPs can be used
as vaccines against the virus from which they are derived, but can also be used
to present heterologous epitopes from other pathogens to the immune system.
Both techniques result in high-titer antibody responses against the target epitope.
Indeed, vaccines of VLPs are already available, including the two vaccines
targeting Human Papillomavirus (HPV). These vaccines are very effective at
preventing infection by the HPV types included in their formulation; high-risk HPV
iv

types that are associated with the development of cervical cancer. The elicited
antibody response, however, largely does not protect against the other high-risk
HPV types. Herein we report the results of studies aimed at developing a nextgeneration HPV vaccine using bacteriophage VLPs displaying epitopes from the
minor capsid protein of HPV L2 that have been found to induce cross-protective
antibodies. We first displayed a variety of N-terminal L2 epitopes on PP7 and Qβ
VLPs and measured the elicited homologous protection in mice. Finding a typespecific neutralizing epitope, we were able to considerably broaden the observed
cross-neutralization by immunizing with a consensus sequence of this epitope
drawn from the high-risk HPV types. We also explored displaying a L2 epitope
from two different HPV types on one VLP. We were able to construct assembled
VLPs that displayed both targets on their surface. We observed that
immunization with these hybrid VLPs elicited a more-cross neutralizing response
than vaccination with VLPs displaying one target alone. Finally, we investigated
the display of two molecular adjuvants on the surface of VLPs. Hypothesizing an
increase in the speed and intensity of antibody response, we displayed both the
complement receptor 2-minimum binding region, p28, and the monomer
component of flagella, flagellin, at low levels on the surface of VLPs. We found,
however, that displaying p28 in this way did not increase antibody titers.
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Chapter 1 – Introduction and Background
1.1 Virus-like particles as vaccine platforms
The expression and self-assembly of viral structural proteins produces viruslike particles (VLPs, see Appendix one for list of abbreviations) [1-3]. These
VLPs are a relatively novel vaccine platform that boasts several advantages over
traditional attenuated or inactivated vaccines[4]. VLPs do not contain viral
genomic material and do not self-replicate, which eliminates the danger of
reversion of attenuated vaccines [5]. In addition, VLPs are strongly immunogenic
and immunologically identical to natural virions, eliciting a robust immune
response against the viral proteins from which they are derived. VLPs can be
made of non-enveloped or enveloped viruses, can be used as a display platform
for heterologous targets and can be produced in a variety of expression systems,
increasing their flexibility and decreasing the cost of production [6-8]. Various
vaccines comprised of VLPs are both currently available and undergoing clinical
trials, representing their utility as an accommodating platform for emerging
vaccines.
1.1.1 Immunogenicity of VLPs
The immunogenicity of VLPs stems from several factors. First, the
epitopes of the viral proteins are displayed in a dense, repetitive array. This multivalent display strongly activates B cells, in part through displaying viral epitopes
in a spacing that has been shown to be optimal for inducing B cells responses [912]. B cells recognize their cognate antigen through binding of the B cell receptor
(BCR) to the pathogen. This binding sets off a signaling cascade that results in
1

proliferation, increased survival, limited production of IgM antibodies, and
movement to germinal centers for affinity maturation and class-switching. The
efficient activation of B cells is based in part upon the affinity of the interaction
between the BCR and its cognate antigen; the stronger the affinity for the target,
the stronger the response. It is also based on the cross-linking of BCRs binding
to a multi-valent antigen, or the avidity of the interaction [13, 14]. An increase in
avidity reduces the affinity threshold of activation for B cells, both in the initial
interaction and subsequent interaction with antigen in the germinal center during
affinity maturation. In this way, a VLP vaccine that provides repetitive sites for
multiple BCRs to bind to increases the avidity of the interaction and promotes a
greater immune response.
VLPs are also intrinsically a similar size and shape as natural virions. This
encourages the efficient uptake by professional antigen-presenting cells (APCs)
[15, 16]. After phagocytosis, the VLP, like any pathogen, is broken down and
displayed on MHC Class II molecules to CD4+ helper T cells, which is necessary
for the efficient activation and class-switching of B cells. In addition, VLP proteins
can be processed for cross-presentation to CD8+ cytotoxic T cells via MHC Class
I molecules [17, 18]. These CD8+ T cells are an important component of the
body’s anti-viral response as they target currently infected cells and kill them,
halting the production of more virions.
Another benefit of VLP vaccines is the longevity of the generated immune
response. In particular, our own lab has studied the immune response to VLPs in
mice and found generated antibody titers to be stable and protective over 18

2

months [19]. Additionally, studies of the immune response to one of the two
Human Papillomavirus (HPV) vaccines, both of which are comprised of HPV
VLPs, have shown long-lasting antibody titers after several years (up to 8.4
years) of surveillance [20, 21].
1.1.3 VLPs as an immunogenic scaffold for heterologous epitopes
VLPs can also be used as a display platform for heterologous epitopes
[22, 23]. This approach allows for the targeting of pathogens or proteins from
which VLPs cannot be normally constructed. Once a suitable epitope is
identified, it is possible to display this target on the surface of VLPs. This can be
particularly useful in the targeting of epitopes within a pathogen that are poorly
immunogenic or masked by non-neutralizing regions in the context of the whole
organism. Remarkably, this method of display has also been shown to be able to
break B cell tolerance of self-antigens, inducing autoreactive antibodies against
the targeted epitope [24]. Heterologous epitope display elicits a high-titer,
monoclonal-like response specifically against the displayed target, something
that whole virion vaccines can fail to generate.
One method used to present foreign peptides is the genetic insertion of
the epitope into exposed loops of a VLP protein [25-28]. This technique requires
knowledge of the structure of the proteins making up the VLP to identify regions
that are exposed on the surface of the VLP and that might be amenable to
insertion. The size and chemical properties of the inserted peptide also
determine the success of this technique. Often these genetic inserts result in the
misfolding of the protein, leaving them unable to self-assemble into the VLP
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N-terminus
C-terminus
AB loop

C-terminus

AB loop
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Figure 1.1 – MS2 and PP7 genetic display of heterologous peptides: A) Schematic of two
dimerized MS2 coat proteins with relevant genetic insertion sites. The AB loop presents the
peptide in a constrained manner, while N- and C-terminal display is less so. B) A representation
of the displayed peptides in the AB loop (left) or the N- or C-terminus (right). The displayed
peptide is only added to one of the coat proteins of the single-chain dimer (SCD), resulting in the
display of 90 peptides per VLP. Images were generated with iMol (http://www.pirx.com/iMol).
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structure. Once a VLP is successfully cloned and found to fold correctly,
however, these chimeric VLPs are technically simple and inexpensive to
produce.
Epitopes can also be linked to the surface of VLPs with chemical linkers
[29-33]. This technique allows for the display both longer peptides and nonprotein targets as it does not affect the folding of the viral proteins. However, the
chemistry of the linkage can preclude certain conjugates. For example, epitopes
with internal disulfide bridges are more difficult to conjugate using chemistry that
requires the sulhydryl group of cysteine residues. Further, the cost of
synthesizing targets to conjugate can be prohibitive. There is no concern about
misfolding of the viral proteins, though, since the VLPs are already assembled.
In either case, using genetic insertion or conjugation, once the target is
successfully displayed, vaccination with these chimeric VLPs leads to antibody
responses against the displayed peptide.
In particular, studies in our lab have focused on bacteriophage VLPs as
vaccine platforms [34-36]. Bacteriophages are non-enveloped, helical and
icosahedral viruses that infect bacteria. The phages used in our lab, MS2, PP7,
and Qβ, are icosahedral with a T-3 symmetry, resulting in 180 coat proteins in
the capsid. These coat proteins can be recombinantly expressed in a number of
different systems, including E. coli, and will self-assemble into VLPs which can
be purified using size-exclusion chromatography. Previous work done by this lab
has identified 3 potential insertion sites for genetic display of peptides in MS2
and PP7: the C- and N-termini and the exposed AB loop [35, 37]. These VLPs,

5

however, suffer from the same constraints as all VLPs in that they are largely
intolerant of the insertion of foreign peptides.
To increase the stability of these coat proteins and allow for the display of
diverse peptides, two copies of the coat proteins are genetically fused to form a
single-chain dimer (SCD) (Fig 1.1A) [38, 39]. Unique enzyme restriction sites
were engineered into the SCD to allow for the genetic insertion of short peptides
(12-15 amino acids) into the downstream coat protein’s AB loop (Fig 1.1B), as
well as the N- and C-termini of the dimer (Fig 1.1C). Display at any of these sites
results in 90 peptides being displayed per VLP and leads to a strong immune
response against the displayed peptide.
Our lab has aslo made use of the small, bifunctional linker succinimidyl 6[(beta-aleimidopropionamido)hexanoate] (SMPH) to conjugate peptides to Qβ
bacteriophage VLPs (Fig. 1.2) [31, 40]. This linker interacts with exposed lysine
groups on the surface of VLPs and free sulfhydryl groups of terminal cysteine
residues. Conjugating with SMPH allows us to potentially attach multiple copies
of a peptide to each of the 180 coat proteins, often resulting in several hundred
peptides being displayed on the surface of each VLP.

6

Qβ Qβ +
only peptide

Unconjugated Qβ

Figure 1.2 – Conjugation of peptides to the surface of Qβ : Qβ VLPs or virions
are incubated with SMPH which binds to exposed lysine residues on the surface.
Then the Qβ-SMPH particles are mixed with peptides with a free sulfhydryl group. B)
SDS-PAGE gel of unconjugated and conjugated Qβ. The ladder of bands in the
conjugated lane represent Qβ monomers conjugated to increasing amounts of
peptide. Each band represents an additional conjugated peptide. Efficient
conjugations results in approximately 300 peptides displayed on the surface.

7

1.2 Second-Generation Prophylactic HPV Vaccines: Successes and
Challenges
Mitchell Tyler, Ebenezer Tumban, and Bryce Chackerian*
Department of Molecular Genetics and Microbiology, University of New Mexico,
Albuquerque, NM 87131, United States
(Published in Expert Reviews Vaccines, 2014 Feb; 13(2):247-55)

1.2.1 Introduction
Human papillomaviruses (HPV) are one of the most common sexually
transmitted pathogens in the world, with a reported 11% world-wide prevalence
in women with normal cytology [41]. In the United States, over 6 million new
HPV infections are reported each year and greater than 20 million people are
currently infected. Over 100 different HPV genotypes have been identified, but
the most common HPV-associated cancer, cervical cancer, is associated with
infection by one of a subset of 14-20 HPVs termed “high-risk” types (reviewed in
[42]). Two high-risk HPV types, HPV 16 and HPV 18, are found in approximately
70% of all cervical cancer cases [43]. Cervical cancer is the second most
common and fifth deadliest cancer in women worldwide, with over 500,000 new
cases and 275,000 deaths each year [44]. Approximately 85% of cervical cancer
cases occur in developing countries [45]. High-risk HPV infection is also
associated with other anogenital cancers (of the vulva, vagina, penis, and anus)
as well as growing percentage of oropharyngeal cancers (reviewed in [46-50]). In
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total, HPV infection is estimated to be responsible for about 5% of human
cancers worldwide [51].
Cervical cancer is one of the few cancers that can be prevented using a
prophylactic vaccine. The current HPV vaccines (Gardasil and Cervarix) are
comprised of a mixture of virus-like particles (VLPs) derived from the HPV major
capsid protein, L1 of two high-risk HPV types (HPV16 and 18). Gardasil also
contains VLPs derived from two low-risk HPV types associated with genital warts
(HPV6 and 11). Both Gardasil and Cervarix have excellent safety profiles and
strongly protect immunized individuals against infection with the HPV types
included in the vaccines [20, 52-55]. However, these vaccines provide modest
cross-protection against other high-risk HPV types, leaving vaccinated individuals
at a decreased risk, but still vulnerable to the development of cancer. This
review will discuss efforts to develop second generation HPV vaccines that will
provide broader protection against the HPV types associated with cancer. In
particular, we will focus on the considerable progress that has been made in
developing vaccines targeting the minor capsid protein of HPV, L2. Vaccines
targeting L2 may provide a relatively simple and effective way to generate crossneutralizing immunity against diverse high-risk HPV types.
1.2.2 HPV Biology
HPV is a non-enveloped double-stranded DNA virus from the family
Papillomaviridae (HPV biology reviewed in [56]). Its circular, covalently-closed
genome is approximately 8kb in length and encodes 8 genes, divided into early
(E) and late (L) proteins. Papillomaviruses have a strict tropism for cells of the
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squamous epithelium and are peculiar in that their life cycle is dependent upon
differentiation of the host cell. In short, upon entering the basal cells, transcription
of the viral genome is regulated by E2. Proteins E6 and E7 interact with p53 and
retinoblastoma protein, respectively, to deregulate the cell cycle and promote
division. As the keratinocytes continue to differentiate and migrate to the skin
surface, the late structural proteins, L1 and L2 are produced to encapsidate the
viral genome and virions are eventually sloughed off from the dead cells.
HPV virions consist of two viral structural proteins, L1 and L2. L1, the
major viral structural protein, assembles into pentamers, 72 of which form an
icosahedral capsid with T-7 symmetry. The minor capsid protein, L2, is present in
much lower amounts than L1, with a maximum of 72 copies per virion at the
vertices [57]. Although both viral capsid proteins are present in virions, natural
HPV infection typically results in the induction of low-titer antibody responses
directed towards L1 only, demonstrating the immunodominance of L1 epitopes
as well as the occlusion of L2. Structural studies have indicated that L2 is poorly
displayed on the surface of mature virions, and is only revealed later in the
complex infection process, presumably after binding of the virion to the basement
membrane, which exposes the amino terminus of L2 [58-60]. Once exposed, 12
or so amino acids at the N-terminus of L2 are cleaved by a furin, a cellular
proprotein convertase, leading to surface exposure of one or more domains of L2
on the virion surface [60-62]. Although HPV virus-like particles (VLPs, described
below) can be formed by L1 protein alone, L2 is required for productive infection.
L2 is required for both HPV endosomal escape and also plays a role in facilitating
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trafficking of the viral genome to the nucleus [62-65]. L2 also plays a critical role
in the encapsidation of viral DNA prior to virion release [66].
1.2.3 HPV cancer epidemiology
While HPV infection is common, infections rarely progress to cancer. It is
thought that most HPV infections are cleared by the immune system.
Nevertheless, persistent infection can occur in a subset of individuals, and this
persistent infection with high-risk HPV types has been shown to be necessary for
the development of cervical cancer (reviewed in [42, 67]). Of the high-risk HPV
types, HPV16 and HPV18 stand out. These two HPV types are found in
approximately 70% of all cervical cancer cases, and HPV16 infection is
associated with 90% of HPV-related oropharyngeal cancers [43, 48], reflecting
the enhanced oncogenic potential of these HPV types relative to other high-risk
HPVs [68, 69]. Although there are geographic differences in HPV genotype
distribution in cancers [68, 70-72], there is strong evidence that about eight HPV
types (namely HPV16, HPV18, HPV31, HPV 33, HPV35, HPV45, HPV52, and
HPV58) are responsible for at least 90% of the global burden of cervical cancer
[73]. Nevertheless, the abundance of high-risk HPV types that cause a small
percentage of cancer cases, and regional differences in these types, complicate
efforts to protect against all oncogenic types and represent a significant hurdle in
efforts to develop a vaccine that provides 100% protection against HPV infection.
1.2.4 Current HPV Vaccines
There are currently two prophylactic HPV vaccines on the market:
Gardasil and Cervarix. Both vaccines contain virus-like particles (VLPs)
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composed of the HPV L1 protein. The development of these vaccines was made
possible by the observation that recombinant L1, when overexpressed,
spontaneously self-assembles into VLPs that structurally resemble infectious
virus but lack genomic material [2, 74, 75]. Randomized clinical trials of HPV
VLP-based vaccines have established that Gardasil and Cervarix are safe and
induce high-titer antibody responses. Importantly, vaccination largely protects
women from HPV16 and 18 DNA acquisition, and the vaccines are remarkably
effective (nearly 100%) at preventing HPV16- and HPV18-associated cervical
intraepithelial neoplasia grade III (CIN III), the precursor lesion for cervical cancer
[52-55, 76, 77]. Notably, studies in the US and Australia have begun to show a
drop in the prevalence of vaccine HPV types both in vaccinated and nonvaccinated populations, indicating that the vaccines may be establishing herd
immunity [76, 77].
Although the precise immunological mechanism of protection by the HPV
vaccines has not been definitely established, it is likely that the protection
provided upon vaccination with HPV VLPs is mediated by neutralizing antibodies.
Both Gardasil and Cervarix elicit high titers of neutralizing antibodies in
vaccinated individuals after intramuscular immunization [78]. HPV neutralizing
antibodies in vaccinated individuals can be measured using sensitive in vitro
neutralization assays that assess the ability of HPV pseudovirus (PsV; HPV
VLPs that encapsidate a reporter plasmid, described in detail in Roberts et al.
[79]) to infect cell lines [80]. In addition, animal studies have shown that
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passively transferred sera from Gardasil-vaccinated mice can protect naïve mice
from cervico-vaginal challenge by HPV PsV [81].
Antibody responses to HPV VLPs are also quite durable. Although
antibody titers drop about 10-fold in the first year after vaccination, levels are
stable thereafter (after 8 years of follow-up, in one study), indicating that the HPV
vaccines provide long-lasting protection [20, 21]. These desirable
characteristics, the induction of high-titer and long-lasting antibody responses,
appear to be general characteristics of VLP-based vaccines. The dense, highly
ordered presentation of L1 on VLPs strongly activates B cells through B cell
receptor cross-linking. Also, VLPs are readily taken up and presented by
professional antigen presenting cells due to their particulate nature (VLPs
reviewed in [7, 82]), further enhancing their immunogenicity. It should be noted
that Gardasil and Cervarix contain an aluminum salt adjuvant that may contribute
to their ability to elicit high titer antibody responses; Cervarix is additionally
adjuvanted with monophosphoryl lipid A (MPL), a Toll-like receptor 4 (TLR4)
agonist. However, clinical trials have demonstrated that even unadjuvanted
HPV VLPs elicit high-titer antibody responses [83], highlighting the innate
immunogenicity of VLP-based immunogens.
One major limitation of the current vaccines is that antibodies elicited by
L1 VLPs are type restricted, in that they largely protect against infection by the
HPV types included in the vaccine and provide suboptimal protection against
other high-risk HPV types (reviewed in [84]). Thus, vaccinated individuals are
still at risk for cancer. The type-restricted nature of neutralizing antibodies
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against L1 has been borne out by epidemiological studies as well as in in vitro
studies using the HPV PsV neutralization assay. Although there is evidence that
the titer and breadth of cross-reactive antibodies are greater after vaccination
with Cervarix than Gardasil [85, 86], in either case the titer of cross-reactive
antibodies is quite low compared to those elicited against HPV16 and 18. There
are also several aspects of the current vaccines that are barriers to worldwide
implementation. Both Gardasil and Cervarix are quite costly, at over US$100 for
each of the three immunizations, though recent agreements brokered by the
GAVI Alliance have lowered the price to a little less than US$5 in as many as 40
developing countries. Also, the vaccine requires a cold-chain which increases
the cost of transportation and storage. Finally, both Cervarix and Gardasil are
given as a recommended three-dose series over an extended six-month period
(although recent data have shown that two doses of Cervarix are as protective as
three doses [87]). Taken together, these factors (price, cold-chain, and
requirement for multiple doses) reduce the uptake of the HPV vaccine in
developing countries, where it is most needed.
1.2.5 Next Generation HPV Vaccines
The next HPV vaccine will need to address many, if not all, of the issues
associated with current vaccines while retaining their effectiveness against HPV
16 and 18. Foremost among them is increasing the number of HPV high-risk
types for which immunization confers protection. One way to address this issue
using the current vaccine technology is to include additional high-risk HPV VLPs
in the vaccine formulation. This strategy has been adopted by Merck, which has
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developed a nonavalent HPV vaccine (V503) that is currently in Phase III trials
(http://clinicaltrials.gov/ct2/show/NCT00543543). In addition to VLPs of HPV
types 16/18/6/11, high-risk types 31, 33, 45, 52, and 58 have been added to the
vaccine. Assuming the vaccine is equally effective against all nine HPV types,
the immunization with V503 will theoretically prevent over 90% of cervical cancer
cases. One study, modeling the increase in protection between current vaccines
and the new nonavalent vaccine, estimates that the decrease in cervical cancer
cases due to the uptake of the new vaccine could range from 9% to 30%,
depending on the region and the amount of cross-neutralization seen after
vaccination [88]. While it is somewhat premature to speculate about this vaccine
since the results of the trial have yet to be published, our experience in animals is
that we can immunize a single animal with a mixture of eight VLPs and still obtain
high titer antibody responses to each of the individual components of the vaccine
[89]. Thus, inducing high-titer antibody responses against the HPV types
included in the formulation is highly possible (although it is also possible that the
levels of neutralizing antibodies against the individual components of the vaccine
may vary). It is likely, however, that V503 will face many of the same barriers to
worldwide implementation as the current vaccines (i.e. high-cost and requirement
of a cold-chain). It is also unlikely that the nonavalent vaccine will be universally
effective against high-risk HPV infection, so Pap screening will continue,
although potentially at reduced frequency.
1.2.6 L2 as the target of Second Generation HPV Vaccines
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Another strategy to increase the breadth of protection conferred by
vaccination is to target the immune response against epitopes that are more
broadly conserved between HPV types. One target that has generated
considerable interest is the HPV minor capsid protein, L2. In studies beginning in
the early 1990s, several labs showed that vaccination with recombinant L2
protein could provide protection from infection with animal papillomavirus [90-92].
Subsequent studies showed that antibodies targeting L2 could not only mediate
homologous neutralization, but could also neutralize diverse papillomavirus types
[93]. Mapping studies have shown that broadly neutralizing epitopes within L2
are located in the N-terminal domain of the protein (roughly amino acids 13-120),
which is consistent with both the sequence conservation of this region and also
the fact that this region of the protein appears to be transiently exposed on the
surface of virions. For example, antibodies raised against the N-terminal 88
amino acids of bovine papillomavirus type 1 (BPV-1) are broadly crossneutralizing against several HPV types, whereas other domains of BPV-1 L2 do
not induce cross-neutralizing antibodies [80]. Subsequent studies have
identified peptide domains within N-terminus that appear particularly promising
targets for vaccines (described in more detail below).
Although vaccines targeting L2 have the potential to cross-neutralization
diverse HPV types, they also have challenges to overcome before they can be a
viable option as a next-generation HPV vaccine. Most prominently, the antibody
titers elicited upon vaccination with recombinant L2 alone are much lower than
those elicited by the L1 VLPs. Furthermore, despite the fact that HPV L2 is
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relatively conserved amongst types, it still displays sequence heterogeneity.
Thus, a broadly effective L2 vaccine will need to protect against as many HPV
types as possible. Of course, this must be done while keeping anti-HPV 16 and
18 neutralizing antibody titers high. Finally, the vaccine needs to be costeffective for uptake in developing countries.
1.2.7 Strategies for Targeting HPV L2.
Most of the efforts to target HPV L2 have focused on vaccines targeting
specific epitopes or domains within the N-terminus of the protein and the use of
different techniques to increase the immunogenicity of L2-derived peptides
(Table 1). Many of these efforts have focused on targeting the L2 domain
encompassing amino acids 17-36. This domain is referred to as the RG-1
epitope because it is targeted by a neutralizing monoclonal antibody (RG-1) that
binds to this region, strongly neutralizes HPV16 and HPV18, and, upon passive
immunotherapy, protects mice from challenge with HPV16 PsV [94]. This region
of L2 contains two cysteine residues (which form a disulfide bond in mature
virions) that are present in all known papillomavirus types [95]. Although this is
a linear epitope, there is evidence that both the oxidation state and structural
context of the RG-1 epitope contributes to its immunogenicity [37, 96]. The RG-1
epitope is not the only potential vaccine target; it has been shown that other
domains within L2 (for example amino acids 108-120 and 69-81) can also elicit
cross-neutralizing antibodies [27, 97, 98].
Because L2 displays some sequence heterogeneity, it is possible that no
single L2 epitope will be capable of inducing antibodies that can cross-neutralize
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Table 1 – Experimental L2-based vaccines
Vaccine Strategy
Recombinant L2
Proteins

Mulivalent display
on Virus-Like
Particles

Recombinant
Bacteria

L2 displayed as
a:
Concatameric
polypeptide

Notable Findings

L2 sequences from multiple
HPV types may broaden
cross-neutralizing
potential and also
increase immunogenicity
by providing a degree of
multivalent display
Lipopeptide
Use of P25, a TLR2
fusion
agonist, may enhance
immunogenicity.
Effective as an intranasal
vaccine
Thioredoxin
Bacterial fusion protein;
fusion
potentially low cost.
Papillomavirus
Also provokes strong antiVLPs
L1 neutralizing antibody
titers against the HPV16
platform
Bacteriophage
Vaccine effective without
VLPs
requiring exogenous
adjuvants
Long-lived immunity; mice
were protected from HPV
pseudovirus challenge 18
months after vaccination
Compatible with genetic
display and chemical
conjugation
Adeno-associated Particles maintain
VLPs
immunogenicity upon
lyophilization
Tobacco Mosaic
Production in plants
Virus and Potato
Virus X
Lactobacteria
Compatible with oral
casei
delivery
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all high-risk HPV types. To account for this possibility, and also to increase the
immunogenicity of a recombinant protein-based vaccine, one strategy has been
to covalent fuse the N-terminal regions of L2 from diverse HPV types together
and expressed this construct as a concatemeric peptide in E. coli [99]. Used with
a variety of adjuvants, these multimeric recombinant vaccines elicit broadly
neutralizing antibodies that were protective against in vivo HPV PsV challenge in
a mouse genital challenge model of HPV infection. For example, a fusion
peptide of HPV L2 amino acids 11-88 from HPV types 1, 5, 6, 16, and 18 (1188x5), injected five times with Freund’s adjuvant, induced high in vitro
neutralization titers against all of the HPV types included in the polypeptide, as
well as types 45, 31, and 58.

In another study, the same 11-88x5 peptide was

mixed with type HPV 16 L1 capsomeres, a structural component of L1 VLPs
comprised of 5 L1 proteins [100]. Capsomeres are less expensive to produce
than the full VLP, but elicited type-specific neutralizing antibodies when used in
vaccination [112]. Coimmunization elicited antibodies that strongly neutralize
HPV16 and also cross-neutralize other HPV types. Finally, in a recent study
attempting to optimize their multimeric peptide by determining essential regions
needed for neutralization, Jagu et al. showed that vaccination with a fusion
peptide displaying the 11-88 region from eight different HPV types to be more
immunogenic than vaccinating with multimeric peptides representing smaller
portions of the same region of L2, implying that the domain contains multiple
neutralizing epitopes and suggesting that immunization with a larger portion of
the N-terminus may increase antibody titers [101].
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Another strategy for presenting L2 epitopes to the immune system is the
use of HPV L1 VLPs as a display scaffold [97, 106, 107]. The rationale for these
studies is that multivalent display of L2 on HPV16 VLPs will enhance its
immunogenicity without sacrificing a strong anti-HPV16 response. The Kirnbauer
group, in particular, has had considerable success inserting L2 peptides into
exposed loops of BPV and HPV16 L1 VLPs [105]. Schellenbacher et al.
genetically inserted overlapping sequences derived from the N-terminus
representing amino acids 2-200 from L2 into L1 proteins and attempted to
generate chimeric VLPs. Although some of the chimeric proteins failed to
assemble into intact VLPs, they found that L1/L2 chimeric VLPs displaying L2 aa
17-36 in combination with adjuvants, provoked the greatest amount of crossneutralizing antibodies in in vitro neutralization assays. Specifically, neutralizing
antibodies were detected against HPV high-risk types 16, 18, 45, 52, and 58, as
well as types 11 and 5. This degree of cross-neutralization was seen when using
Freund’s adjuvant or the more physiologically relevant aluminum hydroxidemonophosphoryl lipid A (Alum-MPL), though at lower titers with Alum-MPL.
Importantly, the insertion of L2 epitopes did not reduce the observed titer of
antibodies directed against the VLP vehicle itself, whether BPV or HPV 16.
Schellenbacher et al. expanded on this study in a recent paper, rigorously
investigating the breadth of cross-neutralization induced by vaccination with HPV
16 L1 VLPs displaying the L2 17-35 (RG-1 VLP) epitope with Alum-MPL [104].
Variable in vitro cross-neutralization titers were observed against all relevant
high-risk types as well as common low-risk and cutaneous types as well. Further,
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immune rabbit sera was passively transferred into mice which were then
challenged with a comprehensive panel of high- and low-risk HPV PsVs.
Protection was seen against all the 21 tested PsVs, even against types for which
the in vitro neutralization titers were quite low. Crucially, this cross-protection
was observed to be long lasting; passively transferred sera drawn 52 weeks after
the initial vaccination was still protective against a heterologous PsV challenge.
A similar technique to increase the immunogenicity of L2 epitopes is to
display them on non-HPV VLPs. Heterologous vaccine targets can be genetically
inserted or conjugated to the surface of VLPs, creating the same dense, ordered
display that strongly activates B cells and leads to high-titer antibody production
against the displayed epitope. This has been accomplished on a number of
different VLPs, ranging from plant viruses to bacteriophages [35, 108-110]. For
example, the Palmer group conjugated the streptavidin bound N-terminus of L2
from canine oral papillomavirus (COPV) to biotinylated Tobacco Mosaic Virus
(TMV) VLPs, showing an increase in anti-L2 antibodies when compared to
immunizing with the L2 peptide alone [110]. Similarly, the Kleinschmidt group
made use of Adeno-associated Virus VLPs (AAVLPs), genetically displaying the
RG-1 epitope (17-36) from HPV 16 and 31 on the same particle [108].
Immunization with montanide ISA 51 as an adjuvant induced high-titer anti-L2
antibodies that were able to neutralize HPV PsVs 16, 31, 18, 45, 58, and 52.
Importantly, Nieto et al. demonstrated that lyophilized and re-constituted AAVLPs
were also immunogenic, provoking anti-L2 antibody production. This finding
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could be advantageous in lowering the cost of storage and distribution of the
vaccine for developing countries.
Our lab has focused on the use of bacteriophage VLPs for the display of
the RG-1 epitope. Bacteriophage VLPs can be produced in bacterial expression
systems, such as E. coli, which lowers manufacturing difficulty and cost while
generating a high yield of recombinant VLPs. Genetically inserting the L2
epitope into an exposed loop on the surface of PP7 bacteriophage coat protein,
we observed induction of high-titer neutralizing anti-L2 antibodies [89]. Notably,
when the RG-1 epitope was inserted in a unconstrained format at the N-terminus
of MS2 bacteriophage coat protein, we observed a marked increase in the crossprotection against diverse HPV types when compared to display in other regions
of the VLP[37]. Using the PsV in vivo challenge model, we observed significant
protection against HPV types 5, 6, 16, 18, 31, 33, 35, 39, 45, 51, 53, and 58 in
mice vaccinated with our L2 displaying VLPs. More recent studies have
examined the longevity and potency of immune responses to bacteriophage
vaccination ([19] and unpublished data). Mice immunized with PP7
bacteriophage VLPs displaying the RG-1 epitope were found to have high anti-L2
titers for at least 18 months after vaccination. These antibodies were also shown
to be protective against PsV challenge after the same time period. We also
measured the immunogenicity of PP7 and MS2 bacteriophages with or without
adjuvants and found the immune response to be only mildly boosted when mixed
with alum, demonstrating the high innate immunogenicity of bacteriophage VLPs.
In another study, we have had some success conjugating L2 peptides to the
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surface of Qβ VLPs, another bacteriophage. We created a consensus sequence
of region aa 65-85 of L2 from the high-risk HPV sequences to increase the crossneutralization of this region and tested the cross-neutralization in an in vitro L2
PsV neutralization assay (assay described in [113]). Sera from mice immunized
with VLPs displaying the consensus sequence showed considerably higher titers
of neutralizing antibodies against heterologous PsV types than those immunized
with non-consensus sequences from the same region.
Finally, L2-derived peptides have been fused to a variety of immuneactivating substances. Richard Roden’s group fused the RG-1 epitope to p25, a
T helper epitope, and P2C, a Toll-like receptor 2 activating lipopeptide [102].
Immunization with this fusion peptide, either sub-cutaneously or intra-nasally,
induced a strong anti-L2 response that was cross-neutralizing in both in vitro and
in vivo PsV neutralization assays. Of note is their observation of a high-titer
response to the intra-nasal immunization, suggesting that this vaccine could be
delivered needle-free, possibly easing its uptake. The Müller group used bacterial
thioredoxin as an adjuvant for L2 peptides, displaying one or more L2 peptides
into a surface-exposed loop of the protein [103]. Inserting a number of small,
overlapping peptides derived from the N-terminus of HPV 16 L2, Rubio et al.
found that immunizing with these thioredoxin constructs with CFA and IFA
adjuvants did induce a strong anti-L2 response. Of the N-terminal regions tested,
they found vaccines that displayed aa 20-38, a peptide overlapping the RG-1
epitope, to induce the greatest breadth of cross-neutralization in in vitro PsV
neutralization assays. Finally, in a rather unique approach, Yoon et al.
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genetically inserted a large region of the N-terminus of L2, aa 1-240, into a
surface protein of Lactobacillus casei (L. casei) [111]. The lyophilized,
recombinant bacteria were given to the mice enterically via intra-gastric gavage,
after which anti-L2 antibodies were found in both sera and vaginal washes.
Immune sera and vaginal washes also cross-neutralized HPV types 18, 45, 58,
and BPV1 in in vitro PsV neutralization assays. Immunized mice were modestly
protected upon in vivo PsV vaginal challenges.
1.2.8 Expert Commentary and Five-year view
Despite the effectiveness of the current HPV vaccines, there remains a
need to provide broader protection against rarer high-risk HPV types and to
make it more affordable for developing countries. While the nonavalent L1-based
vaccine that is in clinical trials may be a potential solution, several groups have
aimed to develop cross-protective vaccines based on L2. Although many labs
have developed strategies to elicit high-titer broadly cross-neutralizing antibodies
against L2, our bias is that multivalent display on VLPs (or some other particulate
carrier) is the most promising and potent technique for eliciting the high titer and
long-lasting antibody responses that may be required for sustained crossprotection. L2-displaying VLP vaccines confer remarkable in vivo crossprotection in HPV PsV challenges against a large variety of HPV types, both
high-risk and otherwise. These studies exhibit the versatility and effectiveness of
VLP-based vaccines in displaying heterologous targets to the immune system.
In all cases, targeting the RG-1 epitope of L2 provokes the broadest crossneutralizing responses. Nevertheless, there remain obstacles that must be
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overcome before any next-generation HPV can be deemed successful, some of
which have been examined in the context of non-VLP-based L2 vaccines. For
example, several groups have looked for ways to reduce the necessity of a coldchain in the delivery of the vaccine. The lipopeptide-L2 construct that was shown
to be effective when delivered intra-nasally is one example; others have
lyophilized their vaccines and shown continued effectiveness. Also, techniques
that are needle-free could possibly ease uptake of the virus. It is possible that
the VLP-based vaccines that have shown so much promise [37, 104, 108] in
cross-protection will also need to incorporate these features in order to be
globally successful. Indeed, our lab has begun to investigate formulation and
long-term storage issues, including whether bacteriophage VLPs can be stored in
a lyophilized format under environmental conditions.
In the long-run, the greatest hurdle may be showing an increase in clinical
effectiveness compared to the upcoming nonavalent L1 VLP vaccine. Clinical
trials of L2-based vaccines will require the establishment of high-throughput and
standardized assays to measure anti-L2 antibody responses and the ability of
patient sera to neutralize diverse HPV types. The recent development of an in
vitro neutralization assay that is optimized to sensitively detect neutralizing L2
antibodies should prove useful for these evaluations [113]. Although L2-based
vaccines have shown effectiveness in preventing infection with cutaneous animal
papillomaviruses [114], it remains to be seen whether these successes will
translate to protection from genital infection by HPV. Finally, the clinical
effectiveness of Gardasil and Cervarix will set a high bar an L2-based vaccine
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and an effective nonavalent vaccine could establish even broader protection for a
second-generation vaccine that would be difficult to surpass. In clinical trials L2based vaccines will need to directly compared to the established HPV vaccines
and the trials will need to powered sufficiently to demonstrate protection against
rare high-risk HPV types. Although these barriers are not insurmountable, they
are substantial.
1.3 Displaying adjuvant-like peptides on VLPs
As has been described above, VLPs are very immunogenic. This immune
response, however, could be potentiated by the addition of adjuvants [115].
Adjuvants are normally included in vaccines as activators of the innate immune
system which further increases the immune response to vaccination. Adjuvants
have the potential to decrease the amount of VLPs needed per immunization,
increase the antigenic memory of the immune response, or even speed up the
production of antibodies. The addition of adjuvant-like moieties to VLPs may
further enhance the immune response to vaccination, and may be useful in the
design of vaccines targeting HPV L2 or other poorly immunogenic epitopes.
1.3.1 p28 as a molecular adjuvant
The body has a number of pathways that enhance immune responses to
pathogens. One is the complement system which leads to the induction of proinflammatory signals, increased adaptive immune responses, and in some cases
destruction of pathogens [116]. Both the classical and alternative pathways of
complement activation involve the cleavage of the complement protein C3 into
C3a and C3b. C3b binds to the surface of pathogens to act as an opsonin,
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coating the particle and increasing the efficiency of its uptake by APCs. C3b can
be further cleaved, leaving a smaller protein, C3d, bound to the surface. C3d is
the ligand of complement receptor 2 (CR2), which is expressed by B cells and
Follicular Dendritic Cells (FDCs) [117]. CR2 binding to C3d in conjunction with
BCR binding of antigen leads to an increase in activation of the B cell, resulting in
greater antibody production [118]. CR2 binding on FDCs can lead to more
efficient affinity maturation of activated B cells and longer immunological memory
[119].
Given its adjuvant-like properties, C3d has been explored as an addition
to vaccines [120]. The minimum CR2 binding region, p28, has been shown to
activate B cells in much the same way that C3d does when presented in a multivalent format [121, 122]. p28 has been utilized in a variety of vaccine studies
where multiple copies are typically fused directly to the antigen of DNA vaccines
and has been shown to increase the antibody titers in response to vaccination
[123-125].
1.3.2 Flagellin – the monomer protein of Flagella
Another possible molecular adjuvant is the principle monomer component
of flagella, flagellin. Bacterial flagella are a Pathogen Associated Molecular
Pattern (PAMP) that is recognized by the immune receptor Toll-like receptor 5
(TLR5) [126, 127]. TLR5 is located at the plasma membrane of epithelial cells
and a number of different immune cells [128]. Binding of flagellin leads to the
induction of pro-inflammatory cytokines, recruitment of B and T cells to lymphoid
tissues, and activation of T cells and dendritic cells [129]. Unlike p28 and other
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immunogenic features of VLPs, flagellin does not interact directly with B cells as
they do not express TLR5. Instead, antibody production is affected indirectly
through activation of other immune cells and general inflammation [130, 131].
Studies have shown that using flagellin as an adjuvant in vaccines, especially
when bound to antigen, results in greater production of inflammatory cytokines
and higher titers of antibodies [132, 133].
1.4 Overview of Dissertation
As discussed above, there is a need for an HPV vaccine that meets the
needs of the countries most affected by cervical cancer. The most important
feature of any next-generation HPV vaccine is that it protect against a greater
number of HPV types, particularly the high-risk types that are found associated
with cervical cancer. Other features include stability of the vaccine at ambient
temperatures, negating the need for a cold-chain of transportation and storage,
affordability, and a minimum number of boosts required for protection. The
inclusion of these characteristics would ease the uptake of the vaccine in
developing countries where a majority of cervical cancer deaths occur.
We hypothesize that using bacteriophage VLPs to display L2 epitopes can
be the basis of a next-generation HPV vaccine. This platform allows us to target
specific epitopes in L2 that are highly conserved or shown to elicit neutralizing
antibodies. In addition, the flexibility of bacteriophage VLPs allows us to
experiment with their construction, including multiple targets or molecular
adjuvants in order to broaden the neutralizing response against heterologous
HPV types and lower the dosage or boosts needed.
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In chapter 2, various epitopes from HPV16 L2 are displayed on
bacteriophage VLPs through genetic insertion or conjugation in order to gauge
their immunogenicity and induced protection when displayed in the dense, highlyordered format of VLP display. We immunized mice with these L2-bacteriophage
VLPs and measured the generated antibody response against the L2 peptides as
well as the protection conferred when challenged with a homologous HPV PsV.
While vaccination with two of these peptides also granted varying degrees of
cross-protection against heterologous HPV types, one, aa 65-85, showed no
cross-protection. This peptide encompassed a region that is poorly conserved
amongst HPV types, and so we hypothesized that immunizing with a consensus
sequence derived from the high-risk HPV types may be more effective at eliciting
a cross-protective response. After immunizing mice with the consensus peptidebacteriophage VLPs, we were able to measure the cross-neutralization of the
generated antibodies through an in vitro neutralization assay developed
specifically to measure neutralizing titers of anti-L2 antibodies. We found that
sera from mice immunized with bacteriophage VLPs conjugated to the
consensus sequence of this region was able to effectively neutralize five different
high-risk HPV PsV types, in contrast to sera from mice immunized with VLPs
displaying aa 65-85 from either HPV16 or 18.
In chapter 3, we investigated displaying multiple targets on the surface of
VLPs. While there are regions of L2 that have great homology among HPV
types, it is possible that only immunizing with one peptide might not be able to
generate an immune response that protects against all the high-risk types. To
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address this, we designed a plasmid that contains two open reading frames of
bacteriophage single-chain dimer. Each dimer displays a different target, and
these self-assemble to form hybrid particles displaying two targets on the
surface. We immunized mice with these hybrid VLPs and compared the immune
responses to that of mice immunized with VLPs displaying the traditional one
target. We found that immunization with the hybrid VLPs could induce an
antibody response against both of the peptides displayed on the surface. In
addition, displaying the same regions of L2 from two closely related HPV types
resulted in a more broadly cross-neutralizing antibody response as well.
Finally, in chapter 5, we investigate displaying p28, the activating peptide
of CR2, and flagellin, the monomer component of flagella, at low levels on the
surface of our VLPs in addition to HPV L2 peptides. By displaying p28, we
sought to mimic the complement system’s own adjuvant-like activities to speed
the immune response to vaccination and reduce the amount of VLPs needed.
Flagellin is bound by TLR5 which isn’t located on B cells but rather on other
immune cells like dendritic cells and T cells. Activating this other immune
pathway could synergistically lead to greater antibody production in response to
our vaccines. We were able to produce VLPs displaying both an HPV L2 epitope
and the p28 peptide on the surface through genetic insertion or a combination of
genetic insertion and conjugation. Displaying the much longer flagellin fragment
proved much more difficult, resulting in misfolding, aberrant translation, or
degradation of the coat protein. Immunizing with these p28 displaying VLPs,
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however, did not result in a faster or more robust production of antibodies against
the included L2 peptide.
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2.1 Abstract
Vaccines targeting conserved epitopes in the HPV minor capsid protein, L2, can
elicit antibodies that can protect against a broad spectrum of HPV types that are
associated with cervical cancer and other HPV malignancies. Thus, L2 vaccines
have been explored as alternatives to the current HPV vaccines, which are
largely type-specific. In this study we assessed the immunogenicity of peptides
spanning the N-terminal domain of L2 linked to the surface of a highly
immunogenic bacteriophage virus-like particle (VLP) platform. Although all of the
HPV16 L2 peptide-displaying VLPs elicited high-titer anti-peptide antibody
responses, only a subset of the immunogens elicited antibody responses that
were strongly protective from HPV16 pseudovirus (PsV) infection in a mouse
genital challenge model. One of these peptides, mapping to HPV16 L2 amino
acids 65-85, strongly neutralized HPV16 PsV but showed little ability to crossneutralize other high-risk HPV types. In an attempt to broaden the protection
generated through vaccination with this peptide, we immunized mice with VLPs
displaying a peptide that represented a consensus sequence from high-risk and
other HPV types. Vaccinated mice produced antibodies with broad, high-titer
neutralizing activity against all of the HPV types that we tested. Therefore,
immunization with virus-like particles displaying a consensus HPV sequence is
an effective method to broaden neutralizing antibody responses against a typespecific epitope.
2.2 Introduction
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The current HPV vaccines (Gardasil and Cervarix) provide strong
protection against two high-risk HPV types, HPV16 and 18, which are associated
with roughly 70% of cervical cancer cases [43], but they largely do not protect
against the other high-risk HPV types that are associated with cancer [84]. To
develop vaccines that provide broader protection against infection by diverse
HPV types, many researchers have investigated the minor capsid protein of
HPV, L2. Although L2 is component of the viral capsid, natural infection with
HPV fails to elicit antibodies against L2. This likely reflects the fact that L2 is only
transiently exposed on the surface of the virus particle during the infectious
process. Upon viral attachment to the basement membrane and furin cleavage,
however, the N-terminal region of L2 is exposed and vulnerable to antibody
binding [58, 62]. Moreover, the N-terminus of L2 includes regions that possess a
great deal of homology among HPV types, suggesting that vaccination with L2
could potentially elicit broadly cross-neutralizing antibody responses. Early
studies using animal papillomavirus models showed that immunization with L2
was protective against homologous and heterologous papillomavirus infection
[90-93]. Epitope mapping studies utilizing neutralizing monoclonal antibodies
targeting the N-terminus of L2 and recombinant peptide-based vaccines have
identified putative neutralizing epitopes within L2 that elicit cross-protective
antibodies [94, 105, 134, 135]. In particular, these studies have identified the
region encompassing L2 aa17-36 as a broadly neutralizing epitope within this
protein. One concern, however, is that vaccination with recombinant L2 typically
results in lower neutralizing titers than vaccination with L1-VLPs [136].
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Much of the success of the current HPV vaccines is due to the strong
immunogenicity of VLP-based antigens. VLPs present viral epitopes in a dense,
repetitive pattern, which leads to the efficient cross-linking of B cell receptors and
high-titer production of antibodies [82]. VLPs can be used as stand-alone
vaccines (as is the case of Gardasil and Cervarix), but they can also be used as
scaffolds to display heterologous antigens in a highly immunostimulatory fashion
[22, 23]. In general, antigens can be displayed on VLPs by genetic insertion of
target sequences into exposed loops on viral structural proteins or by chemically
conjugating target peptides to the surface of VLPs with the use of small, flexible
linkers that react to exposed residues on the surface of VLPs. Both techniques
result in high surface expression of the target antigen and give rise to high titer
antibody responses against the targeted peptide when injected into mice or other
animals [31, 34].
Vaccines in which L2 epitopes are displayed multivalently can induce
potent anti-peptide antibody responses [99, 105, 108]. For example, our
laboratory has displayed a the broadly neutralizing L2 epitope (aa17-31) on VLPs
and has shown that this vaccine elicits high-titer, long-lasting and broadly
neutralizing antibody responses [19, 35, 89]. Here, we hypothesized that this
technique could be used to target other potentially cross-reactive epitopes
derived from L2. Using two different VLP display methodologies, we assessed
the immunogenicity of VLPs displaying a panel of L2 peptides derived from the
N-terminal domain of HPV16 L2. We found that this strategy invariably led to a
high-titer antibody response against the peptide, but the in vivo protection
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observed upon vaginal challenge with HPV pseudovirus was quite varied. In
particular, we found that vaccination with a VLP displaying HPV16 L2 aa65-85
induced strong homologous protection against PsV16, but little to no crossprotection against heterologous HPV PsV types. We were able to overcome this
limitation by immunizing with VLPs displaying a L2 peptide representing the
aa65-85 consensus sequence of high-risk HPV types. Sera from mice immunized
with VLPs displaying the consensus sequence peptide were able to effectively
neutralize heterologous high-risk HPV PsV. We conclude that immunizing with
consensus peptides of neutralizing epitopes may be an effective method to
generate broadly cross-neutralizing antibodies.
2.3. Materials and Methods
2.3.1. Conjugation of L2 peptides to Qβ
Preparation of Qβ bacteriophage was performed as described previously
[31]. Peptides representing 4 regions of the N-terminus of HPV16 L2 (aa34-52,
49-71, 65-85, and 108-120) and a consensus peptide were synthesized by
American Peptide Company (Sunnyvale, Ca). Each peptide was synthesized to
include a cysteine residue at the C-terminus to allow conjugation to
bacteriophage particles. Peptides were conjugated to the surface of Qβ
bacteriophage using the crosslinker SMPH (Thermo Scientific) and conjugation
efficiency was assessed as described previously [31].
2.3.2. Expression & purification of L2 PP7 VLPs
PCR was used to independently insert four HPV16 L2 peptides (aa17–31,
35-50, 51-65, and 65-79) into the AB-loop of the single-chain dimer version of
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PP7 coat protein as previously described [35, 89]. PCR fragments were cloned
into pET2P7K32 using KpnI and BamHI restriction sites and constructs were
confirmed by sequence analysis. VLPs were made by transforming C41 cells
(Lucigen) with L2-PP7 expression vectors. Expression of PP7 VLPs displaying
L2 aa(35-50) and (51-65) also required co-expression of the groEL and groES
chaperones using the plasmid pGro7 (Takara). Transformed cells were grown at
37°C until they reached an A600 of 0.6. L2-PP7 protein expression was induced
with 0.5 mM IPTG for 3h. Cell pellets were lysed and VLPs were purified from the
soluble fraction as previously described [35].
2.3.3. Immunization of mice and characterization of sera for anti L2-IgG
All animal work was done in accordance with National Institutes of Health
and University of New Mexico guidelines. Groups of 3-13 Balb/c mice were
immunized three-times at two-week intervals. Immunizations were performed
intramuscularly (i.m.) using 5 μg of VLPs plus IFA. Sera from all experimental
groups were collected two weeks after the last boost and analyzed by ELISA for
anti-L2 IgG. A peptide ELISA was used to assess the titer of anti-L2 IgG in sera.
ELISA plates were coated with 1 μg of the appropriate target peptide
(representing L2 aa14–40 from HPV16, synthesized by Designer Bioscience, or
aa34-52, 49-71, 65-85, and 108-120 from HPV16 and aa65-85 from HPV18,
synthesized by American Peptide as described above) conjugated to streptavidin
using SMPH. ELISAs were performed as described [89].
2.3.4. Pseudovirus production and purification
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HPV6, HPV16, HPV18, HPV31, HPV45, HPV52, and HPV58 PsVs with
encapsidated reporter plasmid (pClucf) encoding both luciferase and green
fluorescence protein (GFP) genes were produced in 293TT cells as previously
described [79, 137] except that matured PsVs were purified by ultracentrifugation
on a cesium chloride gradient at 27,000xg for 18 hours. Flow cytometry was
used to titer the PsV by determining the fraction of GFP-expressing 293TT cells.
2.3.5. Cervicovaginal HPV PsV challenge
Prior to challenge, female Balb/c mice were given 3 i.m. immunizations of
5 µg of control VLPs or VLPs displaying one of the L2 epitopes. Two weeks after
the last boost, mice were treated with 3 mg of Depo-Provera subcutaneously
(Pharmacia Corp). Five days post-Depo-Provera treatment, mice were vaginally
challenged with 1.3 x 105 – 1 x 107 infectious units (IU) PsV as previously
described [79, 137]. Forty-eight hours post-PsV challenge, mice were vaginally
instilled with 0.4 mg of luciferin (Caliper Life Sciences) and imaged with a Caliper
IVIS Lumina II (Caliper Life Sciences) as described previously [89].
2.3.6. Derivation of an L2 aa65-85 consensus sequence
Twelve high-risk types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and
59) and the three low-risk types (HPV6, 53, and 66) were used to derive a
consensus sequence. L2(65-85) sequences were aligned using ClustalX [138]
and a consensus sequence was generated using Jalview 2.7 [139].
2.3.7. In vitro L2 neutralization assay
Neutralization assays were performed as described in [113] except that
heparin was not added to PsV solutions prior to infection. Following a two-day
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Figure 2.1 - Selection, immunogenicity, and in vivo protection of VLPs displaying L2
peptides. (A) L2 epitopes displayed on VLPs. The reference amino acid sequence listed is that
of HPV16 (Genbank #AAA46942.1). The amino acid conservation of L2 was computed by Jalview
2.7 using the sequences of high-risk HPV types 18, 31, 45, 33, 39, 51, 52, 58, and 59. Vertical
bars represent relative conservation of residues among included types (taller and lighter
indicating greater conservation, shorter and darker indicating less). Red horizontal bars denote
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epitopes genetically inserted into PP7, blue bars denote peptides conjugated to Qβ. The numbers
above each bar represent the HPV16 L2 aa included in the epitopes. (B) Antibody responses
upon immunization with VLPs displaying HPV L2-derived peptides. Mice were immunized with
VLPs displaying the indicated HPV16 L2 peptide or, as a control, with the unmodified VLPs (PP7
or Qβ). Sera were collected and anti-L2 peptide IgG titers were determined by end-point dilution
ELISA using the synthetic peptide displayed on the VLP as a target. End-point dilution titers
indicate the reciprocal of the dilution of serum samples at which reactivity with each of the L2
peptides was at least twice that of background. Data points represent individual mice and lines
represent the geometric mean for each group. (C) Vaccination with VLPs displaying L2 peptides
protects against homologous HPV16 PsV challenge. Mice were immunized with the VLPs (PP7,
left panel; Qß, right panel) indicated on the x-axis and two to three weeks after the last
6
immunization mice were vaginally challenged with 3.0 x 10 IU of HPV16 PsV encapsidating a
luciferase reporter plasmid. Two days after PsV challenge, the mice were vaginally instilled with
luciferin and imaged for luciferase luminescence. Each data point represents the average
radiance for an individual mouse region of interest (ROI) with the line representing the geometric
2
mean of the group. The average radiance (p/s/cm /sr) was calculated by using Living Image 3.2
software. Data were analyzed by one-way ANOVA with Dunnet’s Multiple Comparison
comparing each condition to the control. *** - p ≤ 0.001, ns - not significant.
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incubation, the cells were then collected and analyzed by flow cytometry using a
Hypercyte autosampler to detect GFP expression as a marker of infection. The
dose of PsV used was based on the amount needed to yield 20-40% infection of
control pgsa-745 cells. HPV18 PsV stocks were poorly infectious, so infection
with HPV18 PsV typically resulted in ~10% of control cells being infected.
2.3.8. Statistical Methods
Statistical analyses of in vivo PsV challenges were performed with the
Graphpad 5.0 Prism software. Data was log-transformed and then analyzed by
unpaired, two-tailed t-tests. Multiple comparisons were analyzed by a one-way
ANOVA with Dunnett’s Multiple Comparison Test.
2.4. Results
We have previously shown that a single-chain dimer version of the PP7
coat protein broadly tolerates the genetic insertion of short peptide epitopes,
including aa17-31 of HPV16 L2, allowing the construction of L2-recombinant
VLPs [35]. Immunization with HPV16 L2(aa17-31) (either on bacteriophage
VLPs or using other display formats) induces cross-neutralizing antibodies
against multiple HPV types [94, 102-104, 108]. We asked whether other
domains within the N-terminus of L2 were also capable of inducing neutralizing
and/or cross-neutralizing antibody responses when displayed on a highly
immunogenic VLP platform. In selecting other regions to target through
vaccination, we considered both previous L2 mapping studies and the level of L2
homology among HPV types [134, 135]. In addition to aa17-31, we genetically
inserted HPV16 L2 aa35-50, 51-65, and 65-79 into the AB loop of the PP7
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single-chain dimer (shown schematically in Fig. 2.1A; red lines). In this format,
90 heterologous peptides are displayed on each VLP. Insertion of HPV16 L2
aa35-50 and aa51-65 was compatible with VLP assembly, but insertion of aa6579 was not. We have also had success linking peptides to the surface of Qβ
particles using a chemical crosslinker [31, 140]. While aa17-31 could not be
conjugated due to internal cysteine residues and their required disulfide linking,
we were able to conjugate peptides representing HPV16 L2 aa34-52, 49-71, 6585, and 108-120 to the surface of Qβ (Fig. 2.1A; blue lines). Conjugation of each
peptide was highly efficient; approximately 360 peptides were displayed per Qβ
capsid (not shown).
To assess the immunogenicity of the L2-displaying VLPs, we immunized
groups of Balb/c mice with three 5 µg doses of VLPs displaying L2 peptides or,
as a control, unmodified VLPs (Qß or PP7). Following the last immunization, sera
were collected and analyzed by ELISA for L2 peptide-specific IgG (Fig. 2.1B).
Both types of L2-displaying VLPs elicited high-titers of peptide-specific IgG.
To determine whether vaccination conferred protection from genital
challenge with HPV16, we utilized the HPV PsV vaginal challenge model
developed by Roberts and colleagues [79]. Vaccinated mice were vaginally
challenged with a high dose of HPV16 PsV encapsidating a luciferase reporter
plasmid. Protection against infection was quantified by comparing the luciferase
signal in mice immunized with L2 peptide-displaying VLPs to that of control mice
immunized with the vehicle VLP platform alone (Fig. 2.1C). We found that
vaccination with PP7-16 L2(17-31), Qß-16 L2(65-85), and Qß-16 L2(108-120)
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Figure 2.2 - Mice vaccinated with Qβ-16 L2(108-120) show variable levels of crossprotection from heterologous HPV PsV challenges. Two weeks after their last immunization,
7
groups of mice were vaginally challenged with 10 IU HPV PsV, as described in Fig. 1C. Solid
circles represent mice immunized with wild-type Qβ, empty circles represent mice immunized with
Qβ-16 L2(108-120). Data points indicate the average radiance of individual mice and lines
represent the geometric mean of each group. Data were analyzed by two-tailed, unpaired t-tests
and p-values are listed.
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provided strong protection against homologous PsV infection (>99% decrease in
mean luciferase signal). Conversely, mice immunized with either Qß-16 L2(3452) or recombinant PP7-16 L2(35-50) were poorly protected from HPV16 PsV
challenge. Immunization with either PP7-16 L2(51-65) or Qß-16 L2(49-71)
conferred moderate protection from homologous PsV challenge.
We next investigated whether the vaccines that induced the best
homologous protection also conferred protection from challenge with
heterologous HPV PsV types. Our studies describing the cross-protection
elicited by PP7-16L2(17-31) have been previously published and will not be
reiterated in this manuscript [89]. Mice immunized with Qβ-16L2(108-120)
showed strong cross-protection against PsV18 and 58, moderate crossprotection (~1 log reduction in average luminescence) against PsV6 and 45, and
little protection against PsV31 (Fig. 2.2). In large part, these data agree with
previous studies of this region which show variable cross-neutralization elicited
by immunization with the 108-120 epitope [27, 141].
Immunization with VLPs displaying a peptide representing HPV16 L2
aa65-85 also strongly protected mice from vaginal challenge with HPV16 PsV.
However, mice immunized against HPV16 L2(65-85) were not protected against
an in vivo HPV18 PsV challenge (Fig. 2.3A), suggesting that this epitope was not
cross-neutralizing. To explore this further, we created a vaccine that displayed
the same peptide from HPV18. Sera from mice immunized with either Qβ16L2(65-85) and Qβ-18L2(65-85) were cross-reactive (i.e. recognized both the
homologous and heterologous peptide) in an ELISA assay (Fig. 2.3B). Mice
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despite in vitro cross-reactivity to L2 peptides. Mice were immunized twice with Qβ VLPs
displaying either HPV16 or HPV18 L2(65-85), sera was taken for ELISA analysis and then mice
were challenged with HPV PsV, as described in Fig. 1C. (A) Immunized mice were challenged
5
6
with 1.0 x 10 IU HPV18 PsV or 1.0 x 10 IU HPV16 PsV. Groups of mice were immunized with
the VLP indicated on the x-axis. (B) Serum IgG levels against the HPV18 peptide (left) or HPV16
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peptide (right) were determined as described in Figure 2. Data points indicate the average
radiance of each mouse (A) or the reciprocal endpoint dilution titer of individual mice (B); lines
indicate the geometric mean of each group. PsV 18 challenge data were analyzed by an oneway ANOVA with Dunnett’s Multiple Comparison. * indicates p ≤ 0.05, ns – not significant.
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immunized with Qβ-18L2(65-85) were strongly protected against 18PsV
challenge, but not against 16PsV challenge (Fig. 2.3A). These data are in
concordance with previous studies investigating this region of L2 [134]. Given
that aa65-74 has the same sequence in HPV16 and 18, our findings suggest that
this region of the peptide contains a non-neutralizing, but cross-reactive, epitope.
In contrast, the less well-conserved C-terminal region of this peptide is likely a
type-specific neutralizing epitope. There are several examples of vaccines that
use viral consensus sequences to successfully to induce antibodies with broader
specificities [142-145]. To test whether this strategy would work against HPV L2,
we synthesized a peptide that represented the consensus sequence of aa65-85
from 12 high-risk HPV types and as 3 low-risk types (Fig. 2.4A). Interestingly,
the consensus contains a double proline and a valine-rich region. One of these
motifs is present in nearly all of the high-risk HPV types (Fig. 2.4B). As expected,
mice immunized with Qβ-consensusL2 (65-85) produced sera that reacted with
both the HPV16 and 18 peptides (Fig. 2.4C).
Next, we tested whether the immunization with the consensus peptide
elicited more broadly neutralizing antibodies. In order to establish a more highthroughput assay to measure neutralizing antibodies, we made use of an in vitro
HPV neutralization assay designed specifically to be more sensitive to anti-L2
antibodies [113]. In particular, this assay allows the HPV PsVs to bind to
deposited extracellular matrx (ECM), allowing the N-terminus of L2 to be
processed by the furin-conditioned media and exposing N-terminal epitopes to
anti-L2 antibodies in serum. In addition to quantifying anti-L2 antibodies at a
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Figure 2.4 - Generation of a L2 (65-85) consensus sequence which elicits anti-serum that
exhibits in vitro cross-reactivity to L2 peptides. (A) ClustalX sequence alignment of L2 (6585) from selected high- and low-risk HPV types. The conservation analysis and consensus
sequence was generated using Jalview 2.7, as described in Fig. 3.11A. The numbers after the
HPV types are added by Jalview and indicate the number of amino acids included. The vertical
bars indicate the relative conservation amongst the selection sequences (upper) or to the
consensus sequence (lower). (B) Comparison of the sequence of HPV16 (65-85), HPV18 (6585) and the consensus sequence. Note that the consensus sequence contains two motifs found
in most of high-risk sequences. (C) Immunization with VLPs displaying all three (65-85) peptides
(x-axis) elicit HPV16 and HPV18 peptide-binding antibodies. Serum anti-L2 IgG titers were
determined by end-point dilution ELISA targeting the 65-85 peptide derived from either HPV16
(left) or HPV18 (right), as described in Fig. 1C. Data points represent the endpoint titer of
individual mice and lines represent the geometric mean for each group.
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level that correlates with observed in vivo protection, this assay also allows the
sera from the same mice to be tested for neutralization against a number of
different HPV PsV types. First we measured the neutralization of HPV16 PsV by
sera pooled from vaccinated mice and compared this to the in vivo PsV
challenge results previously obtained (Fig. 2.5A and Fig. 2.1C). We found that
the in vitro results closely mirrored the data from the in vivo challenge. Given
these data, we concluded that the in vitro assay was comparable to the in vivo
challenge model and could be used going forward as a measure of our vaccines’
effectiveness.
To measure the cross-neutralizing activity of serum raised against Qβconsensus L2(65-85), we tested pooled sera for in vitro neutralization against
five high-risk PsVs: 16, 18, 31, 45, and 58 Fig. 2.5B & Fig. 2.6). In general,
pooled sera from mice immunized with VLPs displaying either the HPV16 or the
HPV18L2(65-85) peptide were only poorly cross-neutralizing. We did detect
some cross-neutralizing activity, for example sera raised against Qβ-18L2(65-85)
against the closely related PsV45. Strikingly, pooled sera from mice immunized
with particles displaying the consensus sequence neutralized each of the
different HPV types tested at high dilutions, and was the only serum to neutralize
HPV31 PsV. Thus, these data indicate that displaying a consensus peptide on
Qß bacteriophage can broaden the neutralizing specificity of a region of L2 that
normally only elicits type-specific neutralizing antibodies.
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Figure 2.5 - in vitro PsV L2 neutralization assay. (A) In vitro data recapitulate previous in vivo
PsV challenge data. Sera from mice immunized with VLPs indicated were pooled and tested for
neutralization against HPV16 PsV at ID40 (amount of PsV that infected 40% of cells in wells
devoid of sera) at the indicated dilutions. HPV PsV were incubated on deposited ECM in 96-well
plates and treated with furin-conditioned media. HPV16 PsV was then incubated with pooled
dilutions of sera for 6 hours, after which pgsa-745 cells were added. Infection was measured as
GFP production, quantified by a Hypercyt autosampling flow cytometer. Bars indicate the relative
amount of infected cells in sera treated wells compared to wells with no sera added. In vitro
results were compared to previous (Fig. 1C, right panel) in vivo HPV16 PsV challenge. (B)
Consensus sequence anti-sera neutralizes HPV16 PsV in vitro. Sera from mice immunized with
the VLPs indicated were pooled (5 mice in each group) and tested for neutralization against
HPV16 PsV at ID40 at the indicated dilutions as in (A).
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2.5 Discussion
The N-terminus of L2 contains cross-protective, neutralizing epitopes [134,
135, 146] including the RG-1 epitope, located within aa17-36 of HPV16 [94].
Nevertheless, other epitopes within the N-terminal third of L2 also have potential
to induce neutralizing antibodies. We used two flexible VLP-based approaches to
target candidate epitopes within this region. VLP-display elicited high-titer
antibodies and allowed us to map potential neutralizing epitopes with heightened
sensitivity. We found that targeting aa17-31, 65-85, and 108-120 of HPV16
resulted in near complete protection from homologous HPV PsV challenge.
When vaccinated mice were challenged with heterologous HPV PsV types, we
found variable amounts of protection from type to type in mice vaccinated with
108-120, but little cross-protection in mice vaccinated with 65-85. However, a
consensus sequence peptide derived from this region elicited high-titer crossneutralizing antibodies.
Developing consensus sequence vaccines to elicit a cross-protective
immune response is a technique that has been explored to combat viruses that
undergo antigenic variation. For example, consensus vaccines targeting the Env
protein of HIV show enhanced ability to generate cross-reactive antibodies [145].
Similarly, consensus norovirus VP1 VLPs elicit broader immune response than
VLPs derived from individual norovirus types [142]. Here, we show that this
approach can be extended to a short peptide. One concern with the use of
consensus antigens, however, is that they may induce low-affinity antibodies.
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Such antibodies may be able to react with a greater number of viral strains, but
unable to neutralize any of them effectively. However, the consensus L2 peptide
that we engineered efficiently neutralizes five diverse HPV PsV types. The
potentiated neutralizing activity of antibodies elicited by consensus peptide VLPs
may be due to the inclusion of conserved motifs that are found in most of the
high-risk HPV types. The heterogeneous region of the peptide (aa7685), that likely represents a type-specific neutralizing epitope, contains motifs that
are broadly conserved. A majority of HPV high-risk types include either the
double proline motif or the valine-rich region. Nevertheless, it is worth nothing
that HPV31 does not contain an exact match of either motif, yet was strongly
neutralized by sera from mice immunized with the consensus vaccine.
While we have shown a considerable increase in the cross-neutralization
of heterologous HPV types when vaccinating with a consensus L2 sequence,
there is a high standard of cross-reactivity that will need to be surpassed in order
to be a potential candidate as a next-generation HPV vaccine. In addition to the
current vaccines, a nonavalent L1-based vaccine currently in clinical trials
(http://clinicaltrials.gov/ct2/show/NCT00543543), and other L2-based vaccines
have shown great promise in terms of breadth of neutralization [37, 104]. Any
next-generation vaccine will be required to show an increase in protection
against other high-risk HPV types while still eliciting a strong immune response
against HPV 16 and 18 in addition to being cost-effective, safe, and stable. Given
that the consensus sequence is a single peptide that can be displayed in a
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variety of different vaccine formats and still elicits a cross-neutralizing response,
it could be an effective target for next-generation HPV vaccines.
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3.1 Abstract
Virus-like particles (VLPs) can serve as a highly-immunogenic vaccine
platform for the multivalent display of epitopes from pathogens. We have used
bacteriophage VLPs to develop vaccines that target a highly conserved epitope
from the Human Papillomavirus (HPV) minor capsid protein, L2. VLPs displaying
an L2-peptide from HPV16 elicit antibodies that broadly neutralize infection by
HPV types associated with the development of cervical cancer. To broaden the
cross-neutralization further, we have developed a strategy to display two different
peptides on a single, hybrid VLP in a multivalent, highly immunogenic fashion. In
general, hybrid VLPs elicited high-titer antibody responses against both targets,
although in one case we observed an immunodominant response against only
one of the displayed epitopes.

Immunization with hybrid particles elicited

antibodies that were able to neutralize heterologous HPV types at higher titers
than those elicited by particles displaying one epitope alone, indicating that the
hybrid VLP approach may be an effective technique to target epitopes that
undergo antigenic variation.
3.2 Introduction
Virus-like Particle (VLP) technology is a promising approach for
developing new vaccines. VLPs make attractive vaccines because they are noninfectious and present viral antigens in a dense, ordered manner that leads to
efficient activation of B cells, resulting in high-titer and long-lasting antibody
responses [82, 147]. VLPs can be used as stand-alone vaccines, but they can
also be used as platforms to display practically any antigen in a highly
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immunogenic, multivalent format [22, 23].

Linking target antigens, either

genetically or chemically, to the surfaces of VLPs causes them to be displayed at
high density. This high-density display, in turn, dramatically enhances the ability
of linked antigens to induce potent antibody responses.
Chimeric VLPs can be constructed by genetic insertion of a target epitope
into a viral structural protein [148]. Unfortunately, generation of recombinant
VLPs can be technically challenging because the effects of peptide insertions
into viral structural proteins are notoriously difficult to predict and often lead to
protein folding failures [6, 82].

As a consequence, the engineering of

recombinant VLPs in most systems described to date is a largely empirical
process of trial and error. However, we have engineered the structural proteins
from two related bacteriophages (MS2 and PP7) so that they are dramatically
more tolerant of foreign insertions [34, 35]. These bacteriophages encode a
single structural protein, coat protein, which self-assembles into a 27nm-diameter
icosahedral particle consisting of 90 coat-protein homodimers. While coat protein
monomers of MS2 and PP7 are usually intolerant of genetic insertions, fusing
two copies of coat protein into one long reading frame, which is possible because
the N-terminus of one monomer lies in close physical proximity to the C-terminus
of the other monomer, results in a functional protein that is dramatically more
thermodynamically stable, and highly tolerant of short peptide insertions at two
display sites (the N-terminus and the so-called AB-loop). Recombinant MS2 and
PP7 VLPs created using the single-chain dimer display 90 target peptides on the
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surface of each particle and elicit robust epitope-specific antibody responses
upon vaccination [89, 149, 150].
Many pathogens have developed strategies to evade immunity by
presenting epitopes to the immune system that are antigenically variable, while
hiding highly conserved sites that are essential for protein function [151]. One
example is Human Papillomavirus (HPV). Over 150 different strains of HPV
have been identified and a subset consisting of 14-20 “high-risk” HPV types
causes virtually all cases of cervical cancer [42]. VLPs comprised of the HPV
major capsid protein, L1, are the basis for the HPV vaccines that are currently
available on the market [2, 75]. These vaccines are effective against the two
highest risk types, HPV 16 and 18, which account for approximately 70% of
cervical cancer cases worldwide [53, 54]. However, antibodies raised against L1
VLPs are largely type-specific, thus the vaccines do not provide protection
against other high-risk HPV types. Therefore, there is an impetus to develop
more cross-protective HPV vaccines that will provoke immune responses that will
protect against more of the high-risk HPV types.
In order to develop a more broadly protective HPV vaccine, we have used
a VLP platform approach to target a highly conserved epitope in the HPV minor
capsid protein, L2. L2 is essential for the virus life cycle but is normally shielded
from immune recognition [93]. Previous studies have shown that vaccination
with recombinant L2 elicits immune responses that protect from papillomavirus
infection [90-92] and immunization with epitopes derived from the N-terminal
region of L2 can elicit antibodies that broadly inhibit infection by diverse HPV
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types [104, 146, 152]. In general, the titers of neutralizing antibodies elicited by
recombinant L2 vaccination are, unfortunately, lower than those elicited by
vaccination with HPV L1 VLPs [136]. Further, while anti-L2 antibodies are more
cross-protective than anti-L1 antibodies, the breadth of cross-protection has to be
sufficient to protect against most, if not all, of the high-risk HPV types [89, 94].
As one solution, we have developed vaccines in which we immunize with a
cocktail of VLPs displaying L2 epitopes from different HPV types [89]. However,
there are obvious manufacturing and cost advantages to using a single antigen
that can provoke broadly protective responses.
We hypothesized that one method for broadening protection would be to
display multiple L2 epitopes on the surface of a single VLP. We designed a
plasmid that encodes two open reading frames of bacteriophage coat protein,
each displaying a different epitope. This enabled the production of hybrid VLPs
that display two different epitopes on the same particle in the same highly
immunogenic display context. We hypothesized that these hybrid particles could
elicit antibodies that could bind to both the displayed peptides and other similar
targets as well. We found that immunization with VLPs displaying L2 epitopes
derived from two different high-risk HPV types induced a broader crossneutralizing response than immunizing with VLPs targeting one epitope. These
hybrid particles may be an effective way to broaden the utility of rationally
designed, epitope-based vaccines.
3.3 Methods
3.3.1 Construction of expression plasmids
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PCR was used to independently insert the peptides representing the L2
amino acids 17-31 from HPV 1, 18, and 16, as well as the FLAG epitope into the
AB-loop of the single-chain dimer version of PP7 coat protein (using the
expression vector pET2P7K32) as previously described [35, 89]. Similarly, the L2
sequence representing HPV16 and HPV 31 L2 amino acids 17-31 were cloned
onto the amino-terminus of a single-chain dimer version of the MS2 coat protein
(using the expression vector pDSP62) by PCR as previously described [37]. All
constructs were confirmed by sequence analysis.
3.3.2 Construction of the dual expression plasmid
PCR was used to engineer complementary, unique restriction sites
bracketing the single-chain dimer expression cassette. As a template for the
PCR, we used MS2 or PP7 single-chain dimer expression plasmids containing
insertions in the AB loop (PP7) or at the N-terminus (MS2). The plasmid was
constructed as shown in Figure 1A. Briefly, the upstream expression cassette
was amplified using a forward primer that contained a BglII restriction site and
reverse primer that contained a PstI restriction site. The downstream singlechain dimer was amplified similarly, except that the forward primer included a
PstI restriction site and the reverse primer contained an EcoRI site.

After

amplification, the original plasmid was digested with the BclI (leaving an end
compatible with a Bgl II cut end) and EcoRI. The dual expression plasmid was
then constructed by three-piece ligation and then confirmed by restriction digest
analysis.
3.3.3 Expression, purification, and characterization of VLPs
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Recombinant VLPs were made by transforming C41 cells (Lucigen) with
the PP7 or MS2 expression vectors and VLPs were purified from the soluble
fraction as previously described [35]. Intact VLPs were visualized on a 1%
agarose gel with ethidium bromide (Invitrogen) and quantified by polyacrylamide
gel electrophoresis.
3.3.4 Capture ELISA
ELISA wells were coated with 500 ng/well of RG-1, an anti-L2 antibody
that binds the L2 17-31 epitope (provided by Richard Roden) overnight at 4°C
[94]. The wells were then blocked with 0.5% milk in PBS for one hour. Purified
recombinant PP7 VLPs were added at 5 μg, 1 μg, or 0.5 μg/well for 2 hours at
room temperature. The wells were then probed with a biotinylated anti-FLAG M2
monoclonal antibody (Sigma) diluted 1:2000 for 1 hour at room temperature.
Finally, a HRP conjugated streptavidin (Life Technologies) was added, which
was diluted to 1:4000 for one hour. ABTS was added as the developer and
reactivity was determined by measuring the mean optical density (OD) values at
405 nm.
3.3.5 Immunizations and characterization of antibody responses
All animal work was done in accordance with National Institutes of Health
and University of New Mexico guidelines. Groups of Balb/c mice were immunized
twice intramuscularly (i.m.) at a two-week interval with 5 g of PP7-L2 (displaying
L2 amino acids 17-31 from HPV18, 16, 1, 18/1 or 18/16), or MS2-L2 VLPs 16L2
(displaying L2 amino acids 17-31 from HPV16, 31, or 16/31), or, as negative
controls, unmodified MS2 and PP7 VLPs. Vaccine was prepared with incomplete
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Freund’s adjuvant (IFA). Two weeks after the second immunization, sera were
collected and anti-L2 IgG titers were determined by peptide-based ELISA using
disulfide-constrained L2 peptides representing amino acids 14-40 from HPV1, 5,
6, 16, and 18 (American Peptide company, as described [89])
3.3.6 HPV pseudovirus (PsV) production and purification
HPV6, 16, 18, 31, 45, and 58 PsVs with encapsidated reporter plasmid
(pClucf) encoding both luciferase and green fluorescence protein (GFP) genes
were produced in 293TT cells as previously described [89, 153, 154]. PsVinfectivity titer was characterized using flow cytometry by determining the fraction
of 293TT cells expressing the GFP protein.
3.3.7 Cervicovaginal HPV PsV challenge
Prior to challenge, female Balb/c mice were given 3 i.m. immunizations of
5 µg of control VLPs or VLPs displaying one of the L2 epitopes. Two weeks after
the last boost, mice were treated with 3 mg of Depo-Provera subcutaneously
(Pharmacia Corp). Five days post-Depo-Provera treatment, mice were vaginally
challenged with 1.0 x 105 infectious units (IU) of the PsV stock as previously
described [79, 137]. Forty-eight hours post-PsV challenge, mice were vaginally
instilled with 0.4 mg of luciferin (Caliper Life Sciences) and imaged with a Caliper
IVIS Lumina II (Caliper Life Sciences) as described previously [89].
3.3.8 In vitro L2 neutralization assay
These assays were performed as described in [113] except that heparin
was not added to PsV solutions prior to infection.

Following a two-day

incubation, the cells were then collected and analyzed by flow cytometry using a
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Figure 3.1 - Design and characterization of hybrid bacteriophage VLPs. (a) Design of the
hybrid VLP expression plasmid. Peptide targets can be displayed at either the N-terminus or the
AB-loop of the coat protein single-chain dimer. Each expression cassette is engineered
separately, amplified by PCR, and then plasmids are assembled by three-piece ligation using the
restriction sites listed. PP7 (b) or MS2 (c) VLPs were analyzed using a 1% agarose, nondenaturing gel stained with ethidium bromide (which binds to the genomic material encapsidated
by the VLPs). The mobility of the bands were compared to VLPs of unmodified PP7 or MS2 coat
protein. (d) An alignment of selected HPV sequences representing L2 aa 17-31 (or the
equivalent). Conserved amino acids are indicated in bold text.
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Hypercyte autosampler to detect GFP expression as a marker of infection. The
dose of PsV used was based on the amount needed to yield 20-40% infection of
control pgsa-745 cells. HPV18 PsV stocks were generally poorly infectious, so
cells were infected with amounts of HPV18 PsV resulting in ~10% of control cells
being infected.
3.4 Results
3.4.1 Production and characterization of hybrid VLPs
In order to produce hybrid VLPs, we designed a plasmid that contains two
identical expression cassettes, each containing a T7 promoter, an open reading
frame encoding the single-chain dimer version of either PP7 or MS2, and a
transcriptional terminator (Figure 1A). As a preliminary test of the ability of the
PP7 version of this plasmid to produce hybrid VLPs, we engineered one of the
coat proteins to display a sequence derived from HPV18 L2 (aa17-31) and the
other to display the FLAG epitope. Upon expression, VLPs were purified and
then characterized by agarose gel electrophoresis.

Because VLPs migrate

through the gel due to their overall electrophoretic charge and can be visualized
using ethidium bromide by virtue of the RNA that is encapsidated by the
particles, this assay can be used to measure charge differences that are
conferred by the epitopes that are displayed on the surface of the VLPs. As
predicted, the L2/FLAG hybrid particles show a mobility that falls between VLPs
that display either the L2 or FLAG peptide alone, suggesting that both peptides
are displayed on the surface of the VLPs (Figure 1B).

To confirm this, we

performed a sandwich ELISA, in which an anti-L2 monoclonal antibody was used
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Figure 3.2 - Characterization of PP7-18L2/FLAG hybrid VLPs. (a) Hybrid VLPs were
characterized via capture ELISA. Different amounts of VLPs were added to wells coated with RG1, a monoclonal antibody that binds to the aa 17-31 region of L2, and then probed with a
biotinylated anti-FLAG antibody followed by HRP-labeled streptavidin. Data points indicate the
mean absorption of each well at 405 nm. (b) Mice (three per group) were immunized with 5 μg of
indicated VLPs twice with two week intervals and sera were collected 2 weeks after the last
immunization. Serum anti-L2 peptide or anti-FLAG IgG titers were determined by end-point
dilution ELISA using synthetic peptides. Titers indicate the reciprocal of the lowest dilution of
serum samples at which reactivity with the immobilized peptide was at least twice that of
background. Bars indicated the geometric mean of the group, with error bars indicating standard
deviation.
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to capture the VLPs, and an anti-FLAG antibody was used as a probe, allowing
us to only detect particles that display both peptides on their surfaces. Hybrid
HPV/FLAG particles were detected readily using this assay, whereas VLPs
displaying either the FLAG epitope or the L2 peptide alone were not, indicating
that hybrid particles display both epitopes on their surfaces (Figure 2A).
To assess the immunogenicity of the FLAG/L2 hybrid particles, we
immunized mice and then measured the IgG antibody responses against the L2
and FLAG peptides by ELISA (Figure 2B). Mice immunized with the hybrid
particles made high-titer antibodies that bound to both target peptides.

In

contrast, sera from mice immunized with VLPs displaying only HPV18 L2 peptide
only reacted with the 18L2 peptide. Taken together, these data indicate that our
dual expression plasmid produces hybrid VLPs displaying both peptides on the
surface and can elicit an antibody response against both targets.
3.4.2 Hybrid VLPs can elicit more broadly reactive antibodies against HPV L2
Previous studies in our lab showed that immunization with PP7 VLPs
displaying an HPV16 L2 sequence (aa17-31) elicited antibodies that were only
modestly cross-reactive with L2 sequences from other HPV types [89].

To

determine if hybrid particles could induce more broadly cross-reactive antibody
responses, we produced two hybrid PP7 VLPs that displayed L2 epitopes from
two HPV types (HPV18/1 and HPV18/16 VLPs, respectively). The HPV16 and
18 L2 sequences are closely related (13 of the 15 amino acids are identical),
whereas the HPV1 and 18 L2 peptides are less so (10 of the 15 amino acids are
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Figure 3.3 - Immunogenicity and in vivo neutralizing activity of hybrid VLPs. (a) Groups of
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were vaginally instilled with luciferin and imaged for luciferase luminescence. Each data point
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represents the average radiance for the region of interest (ROI; genital tract) of individual mice;
2
lines representing the geometric mean of each group. The average radiance (p/s/cm /sr) was
calculated by using Living Image 3.2 software. Data were analyzed by a Kruskal-Wallis test with
Dunn’s multiple Comparisons Test; ** indicates p ≤ 0.01, ns, not significant.
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the same; Figure 1D). Analysis of the electrophoretic mobility of the L2 hybrid
VLPs on an agarose gel suggested that the hybrid VLPs incorporated both L2
peptides (Figure 1B). Mice were immunized with either PP7-18L2 VLPs or the
hybrid VLPs and then antibody binding to peptides representing the L2 sequence
from five diverse HPV types was measured by ELISA (Figure 3A). In agreement
with our previous results, the PP7-18L2 anti-serum had strong reactivity to
HPV18 L2, moderate reactivity with L2 peptides from HPV5, 6, and 16, and
including little to no reactivity with the peptide derived from HPV1, which is the
most evolutionarily distant type that we tested [89]. Unexpectedly, immunization
with the PP7-18/1L2 hybrid VLP elicited antisera that only reacted with the HPV1
peptide. There was little reactivity with the other four peptides, including the
HPV18 peptide that was included in the VLP, suggesting that the HPV1 L2
peptide was immunodominant. In stark contrast, the PP7-18/16L2 hybrid VLPs
elicited antibodies that bound strongly to both the 16L2 and 18L2 peptides, as
well as the other three heterologous L2 peptides that we tested, including HPV1.
As a comparison, we also immunized mice with a mixture of VLPs displaying the
HPV16 L2 sequence and the 18L2 sequence alone. The hybrid 16/18L2 VLPs
elicited higher levels of cross-reactive antibodies than the mixture of VLPs, and
only the hybrid VLPs were able to elicit antibody responses that reacted with the
HPV1 peptide. These data indicate that more broadly cross-reactive antibodies
were elicited by hybrid VLPs than by simply mixing two L2-VLPs together.
To assess whether hybrid VLPs were capable of providing protection in
vivo from challenge with a heterologous HPV type, vaccinated mice were
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vaginally challenged with a heterologous HPV pseudovirus (HPV6 PsV)
encapsidating a luciferase reporter (Figure 3B). The mice immunized with the
PP7-18/16L2 hybrid VLPs were the only group that showed a significant
reduction (97.5%) in the geometric mean luciferase signal compared to control
mice vaccinated with wild-type PP7 VLPs.
3.4.3 Hybrid VLPs can enhance the cross-neutralizing potential of an already
potent L2 immunogen
Our lab previously has shown that VLPs that display HPV16 L2 aa17-31 in
an unconstrained fashion at the N-terminus of coat protein can elicit broadly
cross-reactive antibodies that can provide significant in vivo cross-protection from
a panel of eleven diverse HPV PsV types [37]. The one outlier was HPV31,
which was not as strongly cross-neutralized as other HPV types. The sequence
of the HPV16 and 31 L2 epitope only differs by two amino acids, so this result
was somewhat surprising. We hypothesized co-display of HPV16 and HPV31 L2
peptides on a hybrid VLP would enhance the already robust cross-protection. To
test this, we produced hybrid 16/31 MS2 VLPs (Figure 1C) and compared the
antibody responses in vaccinated mice with mice immunized with either MS216L2 or MS2-31L2 VLPs alone, or mice immunized with a mixture of MS2-16L2
and MS2-31L2 VLPs. As shown in Figure 4, immunization with MS2-16L2 VLPs
alone elicited antibody responses with considerable cross-reactivity to a panel of
L2 peptides, whereas MS2-31L2 VLPs elicited antibodies with weaker crossreactivity. Sera from mice immunized with MS2-16/31L2 hybrid VLPs reacted
strongly to all the peptides tested, including HPV1 L2. Thus, co-display of the
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HPV31 peptide on the hybrid VLPs does not detract from the broad crossreactivity that we had previously observed.
To measure the neutralizing activity of antisera, we utilized a new L2
neutralization assay developed by Day et al that is tailored to measure the
neutralization titers developed in response to anti-L2 vaccines (Figure 5) [113].
Sera from mice immunized with MS2-16L2 VLPs neutralized all five of the highrisk HPV PsV types that were tested, but the lowest neutralization titer was
against HPV31 [in agreement with the in vivo data that we had previously
generated [37]]. Serum from mice immunized with MS2-31L2 showed a distinct
pattern of neutralization; this serum strongly neutralized the homologous HPV31
PsV, but neutralized the other HPV PsV types at lower titers. Importantly, serum
from mice immunized with the either the hybrid VLPs or mixed VLPs neutralized
all of the HPV PsV types at high titers. Thus, immunization with hybrid L2-VLPs
can enhance the breadth of HPV neutralization without sacrificing the ability to
neutralize individual HPV types.
3.5 Discussion
The strong antibody responses elicited by peptide epitopes displayed on
VLPs results from the dense, repetitive manner in which the antigen is displayed
to B cells [9]. This multivalent display allows for increased cross-linking of B cell
receptors, strong B cell activation, and enhanced antibody production.

By

displaying two related HPV-derived peptides in highly immunogenic context on
the surface of a single hybrid VLP, we hoped to take advantage of these avidity
effects to activate B cells that could produce antibodies that reacted with a broad
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spectrum of HPV L2-derived peptides and had enhanced neutralizing activity
against diverse HPV types [13]. We anticipated three possible outcomes at the
onset of this study: (1) hybrid VLPs would elicit an immunodominant response
against only one of the two epitopes, (2) the VLPs would elicit antibodies that
against both epitopes, but the response would not be any different from
immunizing with a mixture VLPs displaying each peptide separately, or (3) the
VLPs would elicit a broadly-reactive response that would recognize other similar
epitopes as well. Our results indicated that all three of these outcomes are
possible depending on which peptides are being displayed on the hybrid VLPs.
Immunization with hybrid PP7 VLPs displaying 18/1 L2 elicited high titer
antibody responses against HPV1 L2, but largely failed to elicit antibodies that
bound to four other L2 peptides, including the HPV18 peptide which was
displayed on the VLPs. There are several possible explanations for this result.
First, it is possible that these hybrid VLPs preferentially incorporated the HPV1
L2-displaying coat protein. Although we cannot absolutely rule out this possibility,
analysis of the mobility of the 18/1 hybrid VLP on an agarose gel showed that the
hybrid VLPs displayed an electrophoretic mobility that was midway in between
VLPs displaying only the HPV1 or HPV18 L2 peptides, suggesting that both
peptides are displayed on the VLPs (Fig 1B right). Second, it is possible that
the HPV1 L2 peptide is much more immunogenic than the HPV18 peptide.
Previous studies of the immune response to this region of HPV L2 being
displayed on PP7 VLPs did not show that PP7-1L2 VLPs elicit higher
antibody titers than PP7 VLPs displaying other L2 sequences [89].
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Moreover, co-immunization with a mixture of eight L2-displaying PP7
VLPs elicited balanced responses against our panel of L2 peptides [89].
Third, it is possible that Balb/c mice preferentially responded to the HPV1
peptide due to an increased frequency of precursor B cells specific for the unique
elements in the HPV1 L2 peptide (i.e. immunodominance). Interestingly, when
we immunized a different strain of mice (C57BL/6) with hybrid 18/1L2 VLPs
we also observed immunodominance of the HPV1 L2 peptide (data not
shown). Thus, these data indicate that epitope immunodominance is a potential
consequence when immunizing with hybrid particles. This potential consequence
will need to be carefully evaluated when considering the use of hybrid antigens.
When two highly related L2 peptides were displayed on the same hybrid
VLPs, more broadly reactive antibody responses were generated. Both the PP718/16L2 and MS2-16/31L2 hybrid particles elicited more cross-reactive IgG
responses when compared to that elicited by VLPs displaying only one of the
targets. Hybrid VLPs also elicited more broadly neutralizing antibodies than when
we simply immunized with mixtures of VLPs, indicating that there are distinct B
cell responses to the hybrid particles. In a recent study Nieto and colleagues
displayed two L2 peptides (from HPV16 and 31) at two separate display sites on
adeno-associated VLPs (AAVLPs) [108].

These VLPs elicited strongly

neutralizing antibodies, but antibody responses against one of the peptides
(HPV31) was somewhat weaker, suggesting that one of the display sites on the
AAVLP was less exposed to the immune system. One of the advantages to the
approach that we describe is that both targeted peptides are displayed in the
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same highly immunogenic structural context and spatial arrangement that we
think is critical for induction of high-titer strongly neutralizing antibodies against
HPV [37].
In this study we targeted a single vulnerable neutralizing epitope from
HPV that shows a limited degree of sequence heterogeneity. Although our study
focused on HPV, there are many pathogens that frustrate vaccination efforts due
to antigenic variation and could potentially be targeted using the hybrid VLP
approach.

Similarly, we have shown that hybrid VLPs can also elicit strong

antibody responses against two unrelated epitopes (i.e 18L2 and FLAG). This
feature may be useful for targeting pathogens where more polyclonal antibody
responses are required. In the context of displaying unrelated peptide epitopes,
we think that it is unlikely that hybrid particles will elicit qualitatively distinct
antibody responses than co-immunization with two VLPs. However, there are
certain manufacturing advantages to using a single hybrid VLP as opposed to a
mixture of individual VLPs. Taken together, the use of hybrid VLPs expands the
capabilities of an already useful platform for vaccine design.
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Chapter 4: Display of molecular adjuvants on the surface of
VLPs
4.1 Introduction
Virus-like particles are a promising platform for novel vaccines in large
part due to their high immunogenicity. As discussed above, VLPs have a variety
of characteristics that synergistically work to induce high antibody titers.
Foremost among these is the dense repetitive array in which they present their
epitopes; either components of the capsid proteins that make up the VLP or the
heterologous epitopes displayed on the surface. The combination of potent
immunogenicity and safety, as VLPs do not contain viral genomic material,
makes them doubly attractive as vaccines.
However effective VLPs are, there is always room for improvement. In
particular, uptake of VLP based vaccines, such as the current HPV vaccines,
may be improved in developing countries if there was no cold chain requirement
or if the dosage or number of boosts could be lowered. While there are studies
examining the efficacy of the HPV vaccines after only one dose, three total shots
are still the recommended dosage. Reducing the number of return trips to the
doctor by increasing the immune response to a single vaccination could aid
efforts in inoculating populations.
In order to increase the effectiveness of vaccination and address these
issues, vaccines often include adjuvants [115]. Adjuvants are substances added
to vaccines to potentiate the immune response. Often these substances act to
pool the antigen and slow its release after injection, thereby increasing the time
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of antigen stimulation. Adjuvants can also facilitate the uptake and presentation
of antigen by Antigen Presenting Cells (APCs). Other vaccines include microbe
components that are recognized by the immune system as Pathogen Associated
Molecular Patterns (PAMPs). The binding of the receptors to PAMPs leads to
increased inflammation and stimulation of the adaptive immune system. Studies
have also shown that adjuvants can modulate T cell responses, speed the
reaction to pathogens, and broaden the cross-neutralization of elicited antibodies
[155, 156]. Adjuvants often are essential components of an effective vaccine.
4.1.1 p28: The activating region of complement protein C3d
Similarly, the body has endogenous mechanisms to speed up and bolster
the immune response. One of these mechanisms is the complement system
[116]. Complement plays an important role in the clearance of microbes in part
through opsonization, direct lysing of pathogens, and increased inflammation. A
small aspect of the complement response to pathogens involves C3d, a
downstream product of the cleavage of other complement proteins. All three of
the complement activation pathways result in the cleavage of the protein C3,
either through the activity of the assembled C3 convertase in the classical and
lectin pathways or by spontaneous cleavage in the alternative pathway. This
leaves the C3b fragment that can bind hydroxyl and amine groups on the
surfaces of pathogens through an exposed thioester group [157]. While C3b can
opsonize pathogens, making them easier to be taken up by macrophages and
other APCs, it can also be further acted upon by complement Factor I, cleaving
C3b and leaving the smaller portion, C3d, still bound to the surface of the
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pathogen. C3d is the ligand for the receptor Complement Receptor 2 (CR2),
which is found on B cells and Follicular Dendritic Cells (FDCs) [119]. When a B
cells binds to its cognate antigen on a pathogen CR2 can also bind to embedded
C3d and cross-link with the BCR. This interaction lowers the B cells activation
threshold, reducing the required amount of BCR binding and increasing antibody
production [118, 121, 158].
Germinal center FDCs are a key participant in the process of B cell affinity
maturation. FDCs express Fc receptors and CR2 and are able to capture and
present antibody or C3d-bound antigen to B cells [117, 119]. CR2 binding can
retain the antigen within the germinal center as well as increase the stimulatory
signals that the binding B cells receive in order to survive and become memory
cells. Further, C3d coated antigens will stay in the germinal centers longer,
prolonging the affinity maturation process.
As C3d is a natural adjuvant, there is interest in incorporating it into
vaccines [159]. Previous studies have found that the use of tandem repeats of
p28, the 28 amino acid minimum CR2-binding region of C3d, in DNA vaccines
expressing recombinant antigen can lead to the increased production of
antibodies specific for the fused epitope [120, 123-125]. Thus, we hypothesized
that p28 could potential enhance the immunogenicity of VLP-based vaccines as
well.
4.1.2 Flagellin, the ligand of Toll-like Receptor 5
Another family of immune receptors is called Toll-like receptors (TLRs)
[126, 160]. These receptors are found on a variety of cells including cells of the
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innate and adaptive immune systems. Some are found at the plasma membrane
and bind extracellular ligands while others are located within endosomes and
interact with phagocytosed microbes or antigen. TLRs bind PAMPs; structures
that are common to invading microbes. PAMPs include single-stranded and
double-stranded RNA, lipopolysaccharides, unmethylated single-stranded DNA,
yeast cell wall components and others. Activation of any of the TLRs typically
leads to the induction of pro-inflammatory cytokines, and the recruitment and
activation of various immune cells.
TLR5 is found on epithelial cells and a number of different immune cells,
particularly CD11c+ cells (such as dendritic cells, macrophages, and monocytes)
and T cells but not on B cells [129]. It is located at the plasma membrane and
recognizes flagellin, the monomer component of flagella. TLR5 binding sets off
an immune-activating signaling cascade through the IL-1R pathway resulting in
NF-κB activation. In epithelial cells, flagellin binding results in the production of
cytokines that recruit immune cells to the area [128]. The response of dendritic
cells (DCs) is even more potent [161]. In general, TLR binding activates DCs,
increasing the expression of co-stimulatory molecules their surface and
stimulating the production of cytokines such as IFN-γ. Similar effects have been
shown in T cells [130, 162]. While flagellin can indirectly lead to increased
stimulation of T cells through the activation of APCs like dendritic cells, it can
also act directly on T cells, leading to increased IFN-γ production and cell
proliferation. Flagellin and TLR5 binding has also been shown to promote the
immunosuppressive Treg cells, possibly as a self-regulating mechanism of the
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immune system [163]. Although flagellin does not directly act on B cells, it does
stimulate various cells involved in the efficient activation of B cells. Thus a
relatively small dose of flagellin leads to a large increase in antibody production
[164].
Flagellin has been explored as an adjuvant in various vaccine systems,
either fused to antigen or having antigen genetically inserted into flagellin itself
[132, 165]. For example, linkage of a membrane-bound form of flagellin to
influenza VLPs found that membrane bound flagellin increased the antibodies
responses [133]. Indeed, clinical trials of vaccines that include flagellin as an
adjuvant are ongoing. Bacteriophage VLPs, that activate B cells so strongly,
may benefit from the activation of dendritic cells and T cells that flagellin can
provide.
We hypothesized that display of flagellin or p28 on VLPs could enhance
immunogenicity and could perhaps lead to vaccine dose-sparing effects. Using a
genetic approach, we displayed p28 and flagellin at the C-terminus of MS2 coat
protein. This was accomplished by using an amber stop codon, which allows for
limited read-through of the stop codon in the presence of special tRNAs that are
co-transfected into E. coli with the expression plasmid. Using a low-efficiency
tRNA that allows 1-2% read-through of the amber stop codon, we were able to
purify MS2 VLPs displaying one or two copies of p28 or flagellin. Further, we
were able to display a target from HPV16 on the p28-displaying VLPs through
either genetic insertion or conjugation. We found that co-display of p28 did not
enhance the antibody response against this epitope.
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4.2 Methods and Materials
4.2.1 Construction of p28 peptide by assembly PCR
The mouse analog of the identified CR2 binding site, p28, was taken from
the GenBank file accession number ABD66220. A single copy of p28 or a two
copies in tandem connected with three glycines were constructed by assembly
PCR. In short, two overlapping forward and reverse primers (four forward and
reverse for p28-double) spanning the entire peptide and including a Pst1 site at
the 5’ end and a stop codon and BamH1 site at the 3’ end were constructed by
Eurofins MWG Operon (Huntsville, AL). The first round of PCR contained equal
amounts of all primers and progressed for 8 cycles. The PCR product was then
used as the template for the second round of PCR with only the 5’ and 3’ primers
were used for 25 cycles. This PCR product was then run through a 1% agarose
gel and extracted.
4.2.2 Construction of C-terminal display plasmids
The plasmid pDSP62(am) contains an open reading frame with two
copies of MS2 coat protein genetically fused as a single-chain dimer with an
amber stop codon (TAG), Pst1 site, and BamH1 site sequentially downstream. A
plasmid (pUC57-Kan) encoding Salmonella fliC (one of three flagellin genes,
GenBank accession number NP_460912) flanked by the Pst1 site and four
glycines at the 5’ end and BamH1 at the 3’ end was synthesized by GenScript
(Piscataway, NJ). pDSP62am, pUC57-Kan, pDSP62am and the p28 constructs
were digested with Pst1 and BamH1 and gel purified. The cut fliC and p28
constructs (single or double) were then ligated into the cut pDSP62am
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individually. Correct ligation was confirmed by sequencing. HPV16 aa17-31 was
then ligated into the N-terminus as previously described [37]. Correct ligation
was again confirmed by restriction digest analysis and sequencing.
4.2.3 Expression and purification of VLPs
Recombinant VLPs were made by transforming C41 cells (Lucigen) that
are stably transfected with pNMsupA with the MS2 expression vectors. pNMsupA
uses the replication origin and chloramphenicol resistance of pACYC18422, and
the lac promoter of pUC19 to express an alanine-inserting amber suppressing
tRNA. VLPs were purified from the soluble fraction as previously described [35]
except that chloramphenicol was added (25 mg/ml) during the selection process.
Intact VLPs were visualized on a 1% agarose gel with ethidium bromide
(Invitrogen) and quantified by polyacrylamide gel electrophoresis. LPS was
removed by incubation with Triton X-114 (Sigma-Aldrich) [19]. Triton X-114 was
added at 1% of the total volume of VLP solution, then incubated at 4°C for five
minutes. The solution was then incubated for 5 minutes and centrifuged at
16,000xg at 37°. The supernatant was then transferred to an endotoxin-free
collection tube (MO BIO Laboratories, Inc., Carlsbad, CA). These steps were
then repeated.
4.2.4 Conjugation of HPV16 L2 65-85 peptide to p28 displaying MS2 VLPs
A peptide representing HPV16 L2 amino acids 65-85 was synthesized by
American Peptide (Sunnyvale, CA) to include a C-terminal cysteine residue, to
allow for chemical crosslinking to VLPs. Purified MS2 VLPs with or without Cterminal p28 inserts were conjugated with this peptide as previously described
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[31]. In short, MS2 VLPs were incubated with SMPH (Thermo Scientific) at a
single-chain dimer to SMPH molar ration of 10:1 for two hours at room
temperature. Excess linker was removed using a centrifugal filter unit (100 KDa
cut-off, Millipore) and VLPs resuspended in PBS. The VLPs were then incubated
with the HPV peptide at a 10:1 molar ratio overnight at 4°C. Excess peptide was
removed by centrifugal filtration. Conjugation efficiency was visualized by
polyacrylamide gel electrophoresis.
4.2.5 Characterization of p28 VLPs by ELISA
ELISA wells were coated with 500 ng of MS2 VLPs displaying C-terminal
insertion of p28_single, p28_double (MS2-p28_single or MS2-p28_double) or
wild-type MS2 VLPs overnight at 4°C. 5 μl of mouse sera, containing mouse
complement proteins, in 45 μl of PBS was used as a positive control. Wells were
blocked with 0.5% milk in PBS for one hour. Next, the wells were probed for p28
expression with a goat anti-mouse C3d antibody (R&D Systems, Inc.,
Minneapolis, MN) at dilutions of 1:250, 1:1000, and 1:4000 for 1.5 hours. MS2
VLPs that also displayed HPV16L2 17-31 at the N-terminus were probed
similarly with an anti-L2 antibody, RG-1, provided by Richard Roden [94]. A
HRP-conjugated donkey anti-goat IgG antibody (R&D Systems, Inc.,
Minneapolis, MN) was added to the C3d wells at 1:1000 dilution, and a HRPconjugated goat anti-mouse IgG antibody (Jackson Immunoresearch, West
Grove, PA) was added to the L2 wells at 1:2000 dilution. After addition of the
substrate ABTS the mean optical density (OD) values at 405 nm were
determined.
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4.2.6 Capture ELISA of MS2-fliC-L2 VLPs
ELISA wells were coated with 500 ng of the anti-L2 antibody, RG-1
(described above) overnight at 4°. Wells were then blocked with 0.5% milk in
PBS for one hour. 5 μg, 1 μg, or 500 ng of LPS-removed VLPs were added to the
wells for 2 hours. An anti-flagellin antibody (Abcam Inc, Cambridge, MA) was
added to each well at a dilution of 1:4000 for 2 hours. Binding of the anti-flagellin
antibody was probed with a HRP-conjugated, goat anti-rabbit antibody (Jackson
Immunoresearch, West Grove) at 1:2000 dilution. ABTS was added as the
developer and reactivity was determined by measuring the mean optical density
(OD) values at 405 nm.
For the TLR5 capture ELISA, wells were coated overnight with 250 ng of
soluble, chimeric TLR5 (RD Systems), then blocked with 0.5% milk. A 1:50
dilution of MS2-fliC VLPs or wt MS2 VLPs was added. Wells were then incubated
with a rabbit anti-MS2 antibody (1:2000, 1 hour) followed by HRP goat anti-rabbit
secondary antibody (1:10,000, 1 hour, Jackson Laboratory). Bound
VLP/antibody complexes were detected using ABTS solution (Calbiochem) and
the absorbance was read at 405 nm 1 hour later.
4.2.7 Western Blot of MS2-fliC VLPs
VLP solutions were first separated by gel electrophoresis. Proteins were
transferred from the electrophoresis gel for one hour at 25 V. The membranes
were then blocked in 5% milk. The anti-L2, RG-1, and anti-flagellin (Abcam)
antibodies were added at 1:15000 dilutions, with secondary goat anti-mouse and
goat anti-rabbit antibodies added at 1:20000 (Jackson Immunoresearch). The
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membrane was developed with SuperSignal West Pico Chemiluminescent
Substrate (Thermo Scientific, Rockford, IL) and detected with Blue Basic
autoradiography film (BioExpress, Kaysville, UT).
4.2.8 Immunizations and characterization of antibody responses
All animal work was done in accordance with National Institutes of Health
and University of New Mexico guidelines. Groups of Balb/c mice were immunized
with MS2 VLPs. Mice were immunized with MS2 displaying HPV16 L2 17-31 at
the N-terminus alone or with either p28_single or p28_double at the C-terminus.
The next set of mice was immunized with MS2 conjugated with HPV16 65-85
alone or with either p28_single or p28_double at the C-terminus. Both sets of
mice were immunized with 2 week intervals with sera collected one week after
each immunization. The mice immunized with the N-terminus MS2 were
vaccinated with 250 ng twice and 500 ng once. The mice immunized with
conjugated MS2 were vaccinated with 500 ng three times and 5 μg once. Sera
were analyzed by endpoint dilution ELISA for binding of the target peptide, either
HPV16 17-31 or 65-85, both from American Peptide (Sunnyvale, CA), as
previously described [89].
4.3 Results
4.3.1 Displaying p28 at the C-terminus of MS2 single-chain dimers.
Previous studies utilizing p28 as an adjuvant have shown that a single
copy of p28 can act to inhibit antibody production, but that multiple copies, or
polyvalent p28 ligands enhance B cell activation [120, 121, 124].
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Figure 4.1 – Schematic of pDSP62am: The adjuvant peptide was ligated downstream of an
amber stop codon to allow for limited read-through. E. coli C41 cells were co-transfected with this
plasmid and the pNMSupA plasmid encoding the Sup A tRNA suppressor, allowing low levels of
adjuvant peptide expression.
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Accordingly, we constructed DNA encoding either a single copy or a double
copy of murine p28 with a four glycine linker and ligated it into the pDSP62am
plasmid, downstream
of a single-chain dimer and an amber stop codon (Figure 4.1). Co-expression of
an amber suppressor tRNA can promote translational read-through. The
efficiency of read-through depends on the specific tRNA suppressor cotransfected into the E. coli with pDSP62am. We anticipated that expression of
p28 on every single-chain dimer could result in the inability to assemble into
VLPs or could even lead to an immune response against the p28 peptide [24].
Indeed, we were only able to produce assembled VLPs when we expressed coat
protein in the presence of SupA, which results in a low level of translational
suppression (~1-2%). The use of other suppressors that result in higher
efficiency read-through failed to produce VLPs. These MS2-p28 VLPs were
probed for p28 display by ELISA using a polyclonal anti-mouse C3d antibody
(Figure 4.2A). Although wells containing unmodified MS2 VLPs showed some
background, the p28 displaying VLPs showed as much, if not more, reactivity as
the mouse sera control. This indicated that these VLPs were displaying p28 on
their surface.
We next constructed a plasmid that contained the C-terminal p28 as well
as the HPV16 L2 17-31 epitope. To verify expression of both of these genetic
inserts, we probed the MS2 VLPs with both an anti-L2 antibody, RG-1, that binds
to this region of L2 [94], and the anti-C3d antibody. We found that the VLPs
displaying p28_double and the L2 epitope bound both antibodies, indicating that
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Figure 4.2 – Characterization of p28-displaying and p28/16L2 VLPs: 500 ng of VLPs were
plated and probed with anti-C3d or anti-L2 antibodies to verify expression of the peptide on the
surface of the VLPs. A&B: 500 ng of VLPs were probed by the indicated amount of anti-C3d
antibody. A secondary HRP-conjugated donkey anti-goat antibody was then added and
developed using ABTS. Absorbance was read at 405 nm. Fig 4.2A was allowed to develop
overnight. C: VLPs analyzed as above except an anti-L2 antibody, RG-1, was used. A HRPconjugated goat anti-mouse was used to detect binding. D: Groups of 5 mice were initially
immunized with 250 ng of the indicated VLPs and boosted at week 4 with 500 ng. Data points
indicate the titers of individual mice. Bars indicated the group geometric mean.
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both were present on the surface of the VLPs, while the MS2-16L2-p28_single
VLPs was not bound by the anti-C3d antibody (Figure 4.2B&C). This result
seemed to indicate that the p28_single epitope would similarly not be bound by
CR2.
4.3.2 Immunization with MS2 displaying p28
In order to gauge the effect of p28 display on our VLPs, we immunized
groups of mice with a low dose (250 ng) of MS2-16L2 alone or MS2-16L2p28_double (Figure 4.2D). Sera were taken one and three weeks after
immunization to detect any changes in the kinetics of the antibody response.
Mice were then boosted after four weeks with 500 ng of VLPs, with sera taken
one week after the final immunization. Sera were tested for IgG antibody titers
by peptide ELISA targeting the HPV16 L2 17-31 epitope. Both VLPs elicited hightiter responses against L2. Co-expression of p28_double on the surface of the
VLPs, however, did not enhance anti-L2 antibody titers.
4.3.3 Conjugating an L2 peptide to MS2 VLPs displaying p28
Display of peptides at both the N- and C-termini of MS2 coat protein is
somewhat problematic. These two sites are in close proximity in the assembled
VLPS, so it is possible that there may be steric issues that prevent binding of the
p28 peptide to CR2. Indeed, we observed an anti-C3d antibody failed to bind to
the MS2-16L2-p28_single VLPs. As an alternative method, we displayed a
different HPV16 L2 peptide on the surface of the MS2-p28_single and double
VLPs by chemical conjugation (Figure 4.3A).
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Figure 4.3 – Conjugating a L2 peptide to MS2 VLPs displaying p28 peptides. A)
Electrophoresis gel visualizing the efficiency of the conjugation of HPV16 L2 65-85. MS2 VLPs
with or without p28 peptides were incubated with SMPH and then with the 65-85 peptide with a
terminal cysteine. Each successive band represents a single-chain dimer with another peptide
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conjugated to it. B) Measuring the binding of anti-C3d to conjugated VLPs by ELISA as in Fig 4.2
A. C) Mice were immunized with 500 ng of conjugated VLPs. LPS was removed from all of the
groups except the +LPS control. The low boost sera was taken one week after a 500 ng boost. A
week after, the mice were immunized with 5 μg (high boost) and sera was taken one week after.
Anti-L2 peptide titers were obtained as in Fig 4.2D. Data points represent the titers of individual
mice and bars represent group geometric means.
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To verify that p28 was accessible to the anti-C3d antibody, we again performed
an ELISA to measure its binding (Figure 4.3B). Both MS2-p28_single and double
as well as the conjugated MS2-16L2-p28_single and double bound to the antiC3d antibody, demonstrating that both p28 peptides were, at this point,
unblocked by the conjugated peptides.
4.3.4 Immunization with conjugated/p28 VLPs
We vaccinated groups of five mice with low doses of MS2 16L2 65-85 with
and without the p28 peptide. Since our VLP solutions were contaminated with
bacterial endotoxin, we also compared the immunogenicity of VLPs that had
endotoxin removed and those that had not. We then boosted with a larger dose
(5 μg). Sera were collected one week after the second and third immunizations
(Figure 4.3C). Similar to previous results seen in our lab, the removal of LPS did
not have a significant effect on the endpoint titers elicited by vaccination [19].
Further, the display of p28_single also did not impact the kinetics of antibody
production nor the titers of antibodies produced. Interestingly, the p28_double
VLP consistently showed lower titers than the other sera after the first two
immunizations.
4.3.5 Displaying flagellin at the C-terminus of MS2 single-chain dimers
To create the flagellin displaying VLPs, we followed a similar procedure as
described above. The open reading frame of the Salmonella flagellin gene, fliC,
was inserted at the 3’ end of MS2 single-chain dimer of expression plasmids for
wild-type MS2 and MS2-HPV16 L2 17-31. Due to the large size of the fliC insert
(~1500 base pairs), we co-transfected E. coli with only the lowest tRNA

94

A

B

3

1.0 MS2-FLiC

MS2-FLiC
MS2-16L2
MS2-16L2-FLiC

405

2

Mean OD

Mean OD

405

MS2-16L2

1

0.8 MS2-16L2-FLiC
0.6
0.4
0.2

0

VL
P
g

VL
P
g

.5

anti-FLiC antibody dilution

1

5

g

VL
P

1:
40
00

1:
10
00

1:
25
0

0.0

C

1.0

OD 405

0.8
0.6
0.4
0.2

M

M
S2
-F
L

iC

S2

0.0

Figure 4.4 – Characterization of MS2-FLiC VLPs. A) 500 ng of the VLPs were probed with the
indicated dilution of an anti-FLiC antibody as in Fig 4.2A with a goat anti-mouse 2° antibody. B) A
capture ELISA was performed on LPS removed VLP solutions. The anti-L2 antibody, RG-1, was
used to capture the VLPs, which were then probed with the anti-FLiC antibody. C) Capture ELISA
with 250 ng of a soluble, chimeric TLR5. Wells were blocked with .5% milk then incubated with
the indicated VLPs. An anti-MS2 antibody was added at a 1:2000 dilution then probed with a
HRP-conjugated goat anti-rabbit 2° at 1:10000 dilution and developed with ABTS.
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suppressor plasmid, pNMSupA. We sought to confirm expression of flagellin on
the MS2 VLPs by ELISA with an anti-flagellin antibody (Figure 4.4A). We found,
however, a considerable amount of background in control MS2 solutions. This
seemed to indicate that flagellin from the E. coli used to produce the recombinant
VLPs remains in solution with our purified VLP solutions. We removed LPS by
incubation with Triton X-1114 and assayed the VLPs using two capture ELISAs.
First we used a soluble, chimeric TLR5 to capture the MS2-fliC particles and
probed with an anti-MS2 antibody (Figure 4.4B). Our MS2-fliC was bound by the
TLR5 whereas MS2 was not. Second, we tested the MS2-16L2-fliC VLPs by
capturing them with the anti-L2 antibody RG-1 and probing with the anti-flagellin
antibody (Figure 4.4C). While there was still some background in the control
solutions, the MS2 displaying both L2 and flagellin showed the greatest reactivity.
To confirm that MS2 was displaying flagellin, we performed Western Blots
using the same anti-L2 and anti-flagellin antibodies (Figure 4.5). While the antiL2 blot seemed to show a high-weight band, possibly due to MS2 single-chain
dimer displaying L2 and flagellin, the anti-flagellin blot did not show a
corresponding high-molecular weight band. Indeed, the anti-flagellin blot had a
number of non-specific bands, seeming to indicate that flagellin degradation
products were present in our VLP solutions. Further, the high-molecular weight
band in the anti-L2 had an estimated weight of over 98 kDa, whereas the
predicted weight of the MS2 single-chain dimer, 16L2 peptide, and flagellin is 82
kDa.
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Figure 4.5 - Western Blot with anti-L2 and anti-FLiC antibodies. Endotoxin was first removed
through incubation with Triton X-114. Solutions were then separated on an electorophoresis gel.
Proteins were transferred from the electrophoresis gel for one hour at 25 V. The membranes
were then blocked in 5% milk. Both the anti-L2 and anti-FLiC antibodies were added at 1:15000
dilution, with secondary antibodies added at 1:20000. The membrane was developed with
SuperSignal West Pico Chemiluminescent Substrate and detected with autoradiography flim.
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The high-molecular weight band that reacted with the anti-L2 antibody is difficult
to explain; however, it seems clear that our VLP solutions have a great deal of
flagellin in them, likely masking any effect of our displayed fagellin.
4.4 Discussion
The design of vaccines requires considerations of immunogenicity, safety,
and effectiveness. Virus-like particles have been shown to be potent vaccines
that induce long-lasting, protective immunity. Further, their flexibility as display
platforms creates the opportunity to display adjuvant peptides on their surface. In
addition, VLP vaccines have been shown to be very safe. To enhance the
effectiveness of our VLPs, we investigated displaying two potential adjuvants on
MS2 VLPs: the minimum binding region of C3d, p28 and the monomer protein
component of flagella, flagellin. While we were able to assemble VLPs
displaying these epitopes, various obstacles presented themselves in their
effective implementation.
Primarily, the immunogenicity and adjuvant properties of the VLPs
themselves may have overwhelmed any effect that our displayed adjuvants may
have had. VLPs have been shown to activate B cells to such an extent that they
are able to break B cell tolerance to self-antigens, producing autoantibodies.
Moreover, these VLPs were expressed in and purified from E. coli cells and so
have considerable endotoxin contaminant, a PAMP that is recognized by TLR4
[126]. VLPs additionally encapsidate RNA, which is another PAMP that is
recognized inside the endosomes of phagocytic cells by TLR7. Previous studies
in our laboratory have shown the importance that the ssRNA in our VLPs plays in
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their immunogenicity [19]. Interestingly, LPS removal had little effect. However,
both TLR4 and TLR7 activation lead to similar downstream effects as TLR5 when
binding flagellin [160]. It may be that these endogenous adjuvants, even with
LPS removed, were already having the desired effect of including flagellin on our
VLPs.
The studies of VLPS expressing the flagellin peptide were primarily
confounded by the presence of flagella in our solutions. Despite our purification
efforts, all of our VLP solutions showed reactivity with anti-flagellin antibodies by
both ELISA and Western blot analysis. The capture ELISA, using anti-flagellin
and anti-L2 antibodies to confirm that both targets were being displayed on the
MS2 particles, reacted most with the MS2-16L2-fliC constructs, but also reacted
with preps displaying only 16L2, implying that flagellin was associated with the
VLPs. Production in a different expression system, in plant, mammalian or insect
cells, which would not produce any extra flagella, may be an area where this
adjuvant peptide may be of more use.
C3d is one of the body’s own types of adjuvants, binding to CR2 on B cells
to enhance the elicited antibody response. Other studies have investigated the
use of p28, the 28 amino acid binding region of C3d as an adjuvant and have
seen dramatic increases in the generated titers against the target. Display on
our VLPs, however, seemed to have no effect on either the speed or intensity of
the immune response to vaccination, despite changes in where the target peptide
was being displayed. One possible reason is that the dense, ordered display of
epitopes by VLP already activates B cells to such an extent that CR2 binding
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becomes irrelevant. Surprisingly, vaccination with conjugated MS2-16L2p28_double seemed to result in lower L2 specific antibodies. Previous studies of
p28 have shown that monovalent p28 could inhibit immune response, so it is
puzzling why the double peptide would have that effect. The lower titers,
however, were not noticeable after the larger, 5 μg boost. Other vaccines studies
in which p28 was successfully used were primarily based on recombinant protein
or DNA vaccines [120, 123, 166]. Our VLPs are fully formed capsid particles
which have many more sites that could be bound by endogenous C3d in the
body itself after vaccination. Also, we were only able to display p28 at very low
valency without affecting the correct folding and assembly of the VLPs. At an
estimated one to two copies per VLP, there simply may not have been enough
displayed to achieve the adjuvant effect. Any or all of these factors could have
contributed to the lack of effect.
There are other adjuvants that have been explored for use with VLPs such
as loading empty particles with other TLR activating PAMPs or simply injecting
them with VLPs [167-169]. Adjuvants have the potential to ease the uptake of
new vaccines by reducing the amount of VLPs needed or by lowering the number
of boosts. Further study into the endogenous immunogenicity of VLPs will assist
in targeting new immune-activating pathways that aren’t already being triggered
by the VLPs themselves.
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Chapter 5 – Conclusions
5.1 Summary of research
These studies have focused on optimizing and enhancing the use of
bacteriophage virus-like particles targeting the minor capsid protein of HPV, L2.
We identified a type-specific, neutralizing epitope of L2, amino acids 65-85, that
strongly protected mice from the homologous HPV PsV type, but that did not
protect against heterologous types. We were able to broaden the elicited
neutralizing response through the use of a consensus sequence peptide of that
region derived from the high-risk types of HPV. We were also able to broaden
the cross-reactivity of elicited antibodies by immunizing with VLPs displaying two
peptides. Vaccination with these hybrid particles induced an immune response
against both targets displayed as well as a “hybrid response” that was able to
better neutralize similar heterologous PsVs than antibodies elicited by VLPs with
only one target. Finally, we were able to display two molecular adjuvants on the
surface of VLPs at low levels: the CR2-minimum binding region of C3d, p28, and
the monomer component of flagella, flagellin. Despite using two different
methods to display the L2 epitope, amino acids 17-31, on MS2, the p28 VLPs did
not show any effects on antibody production. Further, the flagellin VLPs were
confounded by the ubiquitous presence of flagellin contaminant in our VLP
solutions.
These projects, though concentrated on L2-displaying vaccines,
demonstrate techniques that could be used in vaccines targeting a variety of
pathogens. Vaccines with consensus sequence epitopes would seem to be of
most use targeting highly mutagenic pathogens with a large number of endemic
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types or strains. Consensus vaccines have already been investigated in studies
of norovirus and HIV as a method of increasing the breadth of cross-protection
generated by immunization. Additionally, incorporating consensus sequences of
type-specific neutralizing epitopes in L1-based HPV VLPs may be a way to
increase the breadth of protection afforded by the current HPV vaccines.
The hybrid vaccines present an alternative method to achieve the same
end of increased cross-protection. By presenting two targets on the VLP, we take
advantage of the high avidity of VLP-B cell interactions to induce an immune
response that, presumably, can recognize both the displayed targets and similar
targets as well. Perhaps the greatest utility of the hybrid display may be the
ability to target two separate epitopes from the same pathogen or two epitopes
from two different pathogens. It is possible that two vaccinations could be
combined into one by displaying both neutralizing epitopes on the same VLP.
The molecular adjuvants that we displayed may be attempting to stimulate
the immune system through pathways already activated by the VLPs themselves.
It is very possible that VLPs are opsonized and tagged with C3d naturally during
immunization like a normal virus would. If this is the case, then our low
expression of p28 would be redundant. Further, we discovered that our VLP
solutions already have flagellin contaminant in them from the E. coli cells used to
recombinantly express them. However, given the variety of expression systems
that can be used to produce VLPs, it is possible that displaying flagellin, at least,
may still be a viable option.
5.2 Future Directions
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One of the strengths of these studies is that the aims synergistically build
upon one another and this is one future direction this research can take. The
neutralizing epitopes identified in Chapter 2, consensus or otherwise, could be
displayed on a hybrid particle. There is some evidence that immunizing against
two HPV16 L2 epitopes increases the heterologous cross-neutralization of HPV
types [135]. We have observed the ability of these hybrid particles to elicit
immune responses against both of the displayed targets. This may be an ideal
way to target two epitopes of L2. Further, L2 epitopes that are fairly well
conserved, such as amino acids 108-120, may benefit from the same type of
hybrid display as performed with the 17-31 epitope. By displaying the 108-120
epitope from two different HPV types, the cross protection we observed in
Chapter 2 could be increased. Finally, while not feasible in this study, both the
consensus and hybrid VLPs may benefit from the display of flagellin as an
adjuvant, if produced in a flagellin-free system and with VLPs that do not
encapsidate unmethylated RNA, another TLR ligand.
In the short term, the immune response elicited by both the consensus
and hybrid VLPs would need to be further tested for neutralization against other
high and low risk HPV PsVs. To be a viable option as a next-generation HPV
vaccine, either would have to demonstrate protection against most or all of the
other high-risk HPV types while equaling the strong protection against HPV16
and 18 generated by the current vaccines.
It would also be worthwhile to investigate genetically inserting the 65-85
consensus sequence into our bacteriophage VLPs. Previous work in our lab has
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shown that inserting this region into PP7 VLPs resulted in misfolded coat protein,
despite the use of chaperone proteins. The cost of synthesizing peptides for
conjugations, however, is such that it could hinder its development for clinical
trials. Possible strategies could include displaying the peptide on MS2 instead of
PP7 or inserting only the consensus sequence of the poorly conserved region of
this peptide, 76-85, that seems to be the neutralizing epitope. It may also be
useful to determine whether displaying a shorter peptide in a more constrained
fashion would affect the cross-neutralization properties of the elicited antibodies,
similar to previous studies in our lab of the L2 17-31 epitope [37].
Among the hybrid vaccines, the immune response against the PP7-18/1L2
stands out as an anomaly. The strong in vitro reactivity with the HPV1 peptide
was expected, but the lack of any reactivity with the other peptides, especially the
HPV18 peptide that was also displayed on the surface of the VLP, was not. The
possible explanation that this skewing of the immune response is caused by an
immunodominant response against the HPV1 peptide requires further study.
Certainly it cautions against the use of hybrid particles in every situation as a
similarly skewed response is a possibility.
The adjuvant studies would benefit from a better understanding of the
body’s response to our VLP vaccines. The inclusion of p28 seemed to be a way
to assimilate an adjuvant-like aspect of the body’s own immune response into our
VLPs. If it were to be confirmed that the VLPs are already bound by C3d during
immunization and activating CR2, then perhaps p28 VLPs administered at a
different site would have more effect. It is possible that VLPs displaying p28 that
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are administered in an alternative route, either through mucosal sites or orally,
would elicit a greater antibody response than those without p28 as they are more
likely to enter local lymphatic tissues before being exposed to complement
proteins in the blood. Thus, the chances of be bound by B cells before serum
complement proteins would be higher.
Also, the finding that p28_double expression seemed to slow the antibody
response runs contrary to previous studies showing that tandem repeats or
polyvalent p28 were immunoactivating. Using in vitro cell-based assays using B
cells incubated with VLPs displaying p28_double, it may be possible to identify
any activated pathways within the B cells which would inhibit antibody
production.
The apparent contamination of our VLP solutions by flagellin needs to be
addressed. While previous studies in our lab have investigated the role of
endogenous and exogenous adjuvants administered with our VLPs, flagellin was
not one that was examined [19]. While it is possible that soluble flagellin not
associated with the VLP would not have a strong adjuvant effect, it is difficult to
say for certain what effect it has on antibody production. Though we were unable
to find a bacterial expression system that was flagellin free, other non-bacterial
VLP expression systems would allow us to measure the effect of displaying
flagellin. Also, a more stringent purification protocol may be able to remove any
soluble flagellin left in our solutions.
5.3 Conclusion
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These studies represent several techniques that could be used in the
rational design of VLP-based vaccines targeting any number of pathogens. Our
bacteriophage VLPs are a highly versatile vaccine platform, as the single-chain
dimer bacteriophage VLPs can tolerate a wide range of genetic insertions. With
the increasing number of neutralizing monoclonal antibodies being discovered
and used as potential therapies, epitope based vaccines like our VLPs may be
able to elicit a robust immune response that mimics the monoclonal therapies but
at a lower cost. Importantly, VLPs that can be rapidly produced and targeted to
neutralizing epitopes may be extremely useful in combating emerging diseases.
As our understanding of how VLPs are processed and elicit such strong immune
responses grows, we will be able to better fine-tune these strategies to the
greatest effect.
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Appendices
Appendix 1 – Abbreviations used
AAVLP – Adeno-associated Virus-like Particles
Alum-MPL - Aluminum Hydroxide-monophosphoryl Lipid A
APC – Antigen Presenting Cell
BCR – B Cell Receptor
BPV – Bovine Papillomavirus
CIN III – Cervical Intraepithelial Neoplasia Grade III
COPV – Canine Oral Papillomavirus
CR2 – Complement Receptor 2
DC – Dendritic Cell
ECM – Extracellular Matrix
FDC – Follicular Dendritic Cell
GFP – Green Fluorescent Protein
HPV – Human Papillomavirus
i.m. – Intra-Muscular
ID – Infectious Dose
IFA – Incomplete Freund’s Adjuvant
IU – Infectious Units
MPL - Monophosphoryl Lipid A
OD – Optical Density
PAMP – Pathogen Associated Molecular Pattern
PsV – Pseudovirus
ROI – Region of Interest

107

SCD – Single-chain Dimer
SMPH - Succinimidyl 6-[(beta-aleimidopropionamido)hexanoate]
TLR – Toll-like Receptor
TMV – Tobacco Mosaic Virus
VLP – Virus-like Particles
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